Chapter I: Ocular Health and Ocular Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the ocular system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the ocular system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the ocular system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for ocular disorders.

The Endocannabinoid System and THC and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, the gastrointestinal tract, musculoskeletal system, and endocrine system. Cannabinoid receptors CB1 and CB2 facilitate

the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells. The direct effects of endocannabinoids on multiple organ systems correlates with the clinical outcomes in such conditions as hyperinsulinemia, diabetes, atherosclerosis, cardiovascular disease, and obesity. Because some phytocannabinoids, cannabinoids of the cannabis plant, and hemp cannabidiol (CBD) mimic components of the endocannabinoid system of the human body, the effects are of interest in the medical management of multiple disorders, including disorders of the ocular system, which is directly affected by the immunological and cardiovascular systems. Indeed, research indicates that both THC and cannabidiol (CBD) have neuroprotective and therapeutic ocular benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol, derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of oxidative ocular disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects that are beneficial in the prevention and management of certain ocular disorders.

Human Ocular System
The human eye is an asymmetrical globe, approximately one inch in diameter, comprised of five major components; the iris, cornea, pupil, sclera, and conjunctiva. The interpretation of vision is articulated as light projects through the pupil, a circular opening, and the lens, which allows the focus of light onto the rear (posterior) portion of the eye. The retina, which is collection of light-sensing cells, converts light into electrical impulses that are signaled to the brain. Central vision is controlled by the macula, a small, highly sensitive area located inside the retina, and the fovea, a small depression within the macula, which provides the most acute vision. Genetic dominance influences the color of the eye, located within the iris, the pigmented area covered

by the clear dome called the cornea. The eye is protected by a fine layer of tissue which covers the anterior (front) of the organ, with the exception of the cornea.

Medical Cannabis and Cannabidiol (CBD): Ocular Disorders and Diseases
Diseases of the ocular system directly related to oxidative stress include retinal diseases such as glaucoma, uveitis, macular degeneration, and diabetic retinopathy. The human body evokes an active inflammatory response to mitigate damage from injury or infection via microglial cell and macrophage release. However, activation of microglial cells and macrophages is also associated with the release of glutamate, reactive oxidative species (ROS), nitric oxide (NO), and tumor necrosis factor (TNF), causing an escalation of inflammation, vascular deterioration, and neurodegradation. THC and cannabidiol (CBD), according to El-Ramessay and Tang (2008), block the oxidative stress response and activation of proteins such as p-38 MAPK and microglial cells, providing neuroprotection to the retinal ganglion cells. Further, THC in cannabis sativa possesses anti-inflammatory and analgesic effects, according to Formukong and Evans (1988), warranting consideration in the management of ocular disorders.

Glaucoma
Glaucoma describes an array of ocular disorders associated with intraocular pressure imbalance, both elevated and normal to low, with associated loss of retinal ganglion cells, nerve damage, and visual loss, leading to possible blindness. Glaucoma is either categorized as open angle (slow onset and progression) or closed angle (painful and rapid progression) and pertains to the angle between the iris and the cornea through which fluid flows as a part of the trabecular network. Because the incidence of glaucoma increases exponentially with age, the neuroprotective benefits of cannabidiol (CBD) are of particular interest.

Research indicates that the release of excessive glutamate, a vital neurotransmitter normally present in retinal ganglion cells, induces ischemia-related neurotoxicity and cell death. Cannabidiol (CBD) has been demonstrated as a non-psychoactive antioxidant which reduces the production of reactive oxygen species (ROS). El-Remmessey demonstrated in 2003 that cannabidiol (CBD) is neuroprotective against glutamate-induced retinal injury, preventing formation of lipid peroxides, nitrite and nitrate compounds, and nitrotyrosine, the physiological basis for the development of glaucoma.

Research indicates that THC decreases intraocular pressure by dilating microvasculature leading away from the anterior uvea in the eye, thereby reducing the ultrafiltration pressure in aqueous humor formation (Green, Wynn, Padgett, 1978). Additionally, THC has been shown to reduce the retinal ganglion cell death induced by glaucoma through the reduction in intraocular pressure (Cranfurther, the dall, Matragoon, Khalifa, et.al, 2007). Exploration of the use of non-psychoactive cannabidiol (CBD) in glaucoma prevention and management, and cannabis sativa, which possesses high levels of THC, in the treatment and management of glaucoma, are warranted in view of the literature.

Uveitis
Uveitis describes a collective group of inflammatory ocular diseases, which produce edema and tissue destruction leading to vision loss or blindness. While the uvea of the eye is affected, other physiological components such as the lens, retina, optic nerve, and vitreous humor are likely

targets. Anterior uveitis, (associated with rheumatologic and infectious diseases), intermediate, (associated with sarcoidosis and multiple sclerosis), posterior (associated with choroiditis and infectious diseases), and panuveitis (associated with Behcet's disease), respond to anti-inflammatory effects of cannabidiol (CBD) after the occurrence, according to Liu and Khalifa (2005). Preventatively, cannabidiol (CBD) was found to exert neuroprotection against uveitis via the blockage of oxidative stress and damaging effects of endotoxins.

THC has been demonstrated to induce anti-inflammatory responses in the retina, vitreous humor, and optic nerve, lending medical application of cannabis sativa to the management of uveitis as well. THC appears to antagonize the CB2 receptors, evoking an immunomodulatory effect in the human and animal subjects. Research supports the consideration of both cannabidiol (CBD) and THC in the prevention and management, respectively, of uveitis associated with autoimmune and traumatic injury (Abrams, Couey, Shade, et.al, 2011).

Macular Degeneration
Two forms of age-related macular degeneration are associated with vision loss in individuals over the age of sixty years. The dry form causes the distortion of vision through the deposits of drusen, or yellow matter in the macula. The wet form, which is characterized by the growth of abnormal blood vessels from the choroid beneath the macula, distorts vision and has an increased likelihood of causing central blindness. The activation of microglial cells of the retina in dry macular degeneration enhances tissue damage caused by the underlying inflammatory disorder. Research indicates that cannabidiol (CBD) provides effective neuroprotective and anti-inflammatory properties, information of critical importance in geriatric medicine. Consideration of the preventive use of cannabidiol (CBD) may be warranted with introduction in the young adult (Tan JS, Wang JJ, Flood, V, et. al., 2007).

THC possesses anti-VEGF (anti-Vascular Endothelial Growth Factor) properties, which reduces the formation of aqueous vitreous humor and enhances regression of abnormal blood vessels in the eye (Ibid., 2007). In combination with nutritional supplements, medical cannabis may be considered to decrease the incidence of conversion from dry macular degeneration to the vision-threatening wet form.

Diabetic Retinopathy
Diabetic retinopathy is associated with the deterioration of the blood-retinal barrier and cell-death of the retinal ganglion cells, culminating in visual loss. The dysregulation of glucose metabolism, which is characteristic of diabetes mellitus, enhances cell hyperpermeability in the retina, increasing the susceptibility of injury by reactive oxidative species (ROS). Cannabidiol (CBD) has been demonstrated to reduce oxidative and nitrative stress in diabetic retinas by maintaining the integrity of the blood-retinal barrier through blockage of glutamate accumulation and neuronal cell death. Research suggests assessing the use of cannabidiol (CBD) in diabetes to reduce inflammation and provide neuronal protection, essential to the prevention of diabetic retinopathy.

Research indicates that THC has an immune modulator effect that inhibits the severity of the autoimmune response in diabetic retinopathy, which occurs when elevated levels of glucose triggers the oxygen deprived retina to grow excess blood vessels, which progressively leads to

blindness. Additional damage occurs with the activation of microglial cells, which are responsible for the removing the dying nerve cells, producing a damaging autoimmune response. THC has been found to decrease hyperinsulinemia systemically, which reduces the potential for diabetic retinopathy and regulates the intensity of the immune response to retinal ganglion cell death. Research indicates that Cannabidiol (CBD) and medical cannabis possess neuroprotective properties, which may reduce the incidence of diabetic retinopathy and the degree of ocular damage in the advent of disease.

CEN Medical Cannabis Pharmacological Prescription and Coding System: **Ocular Disorder Application**
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: The cannabis sativa strain recommendation is 13% to 20% and the CBD percentage is .05% for glaucoma. The prescription would therefore read:

Mary Jane Rider
Date of Birth: 03-09-1950.
Diagnosis: Open-Angle Glaucoma (ICD-9 code: 365.05)
CS: 13%/ .05%. Use via a vaporizer twice daily for one month.
Rich Jones, M.D.

The patient would then travel to a dispensary and provide the dispensary technician with the prescription. The technician would provide the patient with choices of medical cannabis strains meeting the physician's criteria, and fill the prescription accordingly.

Composition Assignments

1. Please answer the following question: Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with diabetes retinopathy.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the ocular system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Belgrave BE, Bird KD, Chesher GB, et al. The effect of cannabidiol, alone and in combination with ethanol, on human performance. *Psychopharmacology* (Berlin). 1979; 64:243–246.

Chen June (2006). Abnormal cannabidiols as agents useful in combination therapy for lowering intraocular pressure. *United States Patent Application Publication* (US 2006/0247321).

Chen, June &David F. Woodward (2005). Abnormal cannabidiol as neuroprotective agents for the eye. *United States Patient Application Publication* (US 2005/0282912).

Crandall, James, Surapporn Matragoon, Yousuf M. Khalifa, Caesar Borlongan, Nai-Tse Tsai, Ruth B. Caldwell, & Gregory I. Liou (2007). Neuroprotective and intraocular pressure-lowering effects of (-)Δ9-tetrahydrocannabinol in a rat model of glaucoma. *Ophthalmic Research*, 39, 69-75.

Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology*. 1980; 21:175–185

El-Remessy, A. B., Y. Khalifa, S. Ola, A. S. Ibrahim, & G. I. Liou (2010). Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. *Molecular Vision*, 16, 1487-1495.

El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai N-J, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. *Am J Pathol*. 2006; 168:235–244.

Goldberg, Ivan, Michael A. Kass, & Bernard Becker (1976). Marijuana as treatment for glaucoma. *Australian Journal of Ophthalmology*, 151-157.

Green, Keith, John F. Bigger, Keun Kim, & Karen Bowman (1977). Cannabinoid action on the eye as mediated through the central nervous system and local adrenergic activity. *Experimental Eye Research*, 24, 189-196.

Green, K., J. F. Bigger, K. Kim, & K. Bowman. (1977). Cannabinoid penetration and chronic effects in the eye. *Experimental Eye Research*, 24, 197-205.

Green, Keith, E. Claire Kearse, & Orinthal L. McIntyre (2001). Interaction between delta-9-tetrahydrocannabinol and indomethacin. *Ophthalmic Research*, 33, 217-220.

Green, Keith, Henry Wynn, & Karen A. Bowman (1978). A comparison of topical cannabinoids on intraocular pressure. *Experimental Eye Research*, 27, 239-246.

Green, K., H. Wynn, & D. Padgett. (1978). Effects of Δ9-tetrahydrocannabinol on ocular blood flow and aqueous humor formation. *Experimental Eye Research*, 26, 65-69.

Hampson AJ, Grimald M, Axelrod J, Wink D. Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. *Proc Natl Acad Sci* U S A. 1998; 95:8268–8273.

Järvinen, Tomi David W. Pate, & Krista Laine (2002). Cannabinoids in the treatment of glaucoma. *Pharmacology & Therapeutics*, 95, 203-220.

Krupin, Theodore, Carol Fritz, John J. Dutton, & Bernard Becker (1980). Δ9-tetrahydro-cannabinol transport in rabbit eyes. *Experimental Eye Research*, 30, 345-350.

Lax, Pedro, Gema Esquiva, Cesare Altavilla, & Nicolás Cuenca (2014). Neuroprotective Effects of the cannabinoid agonist HU210 on retinal degeneration. *Experimental Eye* Research, 120, 175-185.

Liou, Gregory I., John A. Auchampach, Cecilia J. Hillard, Gu Zhu, Bilal Yousufzat, Salman Mian, Sohail Khan, & Yousuf Khalifa (2008). Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2a adenosine receptor. *Investigative Opthalmology & Visual Science*, 49(12), 5526-5531.

Liou, G. I., A. B. El-Remessy, A. S. Ibrahim, R. B. Caldwell, Y. M. Khalifa, A. Gunes, & J. J. Nussbaum (2010). Cannabidiol as putative therapy for diabetic retinopathy: a postulated mechanism of action as an entry point for biomarker-guided clinical development. *Current Pharmacogenomics of Personalized Medicine*, 7(3), 215-222.

MacIntyre, Jessica, Alex Dong, Alex Straiker, Jiequan Zhu, Susan E. Howlett, Amina Bagher, Eileen Denovan-Wright, Dao-Yi You, & Melanie E. Kelly. (2014). Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. *European Journal of Pharmacology*, 735, 105-114.

Pinar-Sueiro, Sergio, José Ángel Zorrilla Hurtado, Patricia Veiga-Crespo, & Sansar C. Sharma (2013). 55212Neuroprotective effects of topical CB1 agonist WIN 55212 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. *Experimental Eye Research*, 110- 55-58.

Pinar-Sueiro, S., R. Rodríguez-Puertas, & E. Vecino (2001). Cannabinoid applications in glaucoma. Archivos de la Sociedad Española de Oftalmología, 86, 16-23.

Porcella, Anna, Chiara Maxia, Gian Luigi Gessa, & Luca Pani (2001). The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. *European Journal of Neuroscience*, 13, 409-412.

Russo, E. B., A. Merzouki, J. Molera Mesa, K. A. Frey, & B. J. Bach (2004). Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco. *Journal of Ethnopharmacology*, 93, 99-104.

Shen, Katherine (2014). Medical marijuana for glaucoma therapy. *Glaucoma Today*, May/June, 46-51.

Stumpfl, Friederike, Marianne Boxberger, Achim Krauss, Rita Rosenthal, Susann Meissner, Lars Choritz, Michael Wiederholt, & Hagen Thieme (2005). Stimulation of cannabinoid (cb1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. *Experimental Eye Research*, 80, 697-708.

Tezel, G, Yang X, Luo C, Peng Y, Sun SL, Sun D. Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. *Invest Ophthalmol Vis Sci*. 2007;48:705–714.

Toguri, J. T., C. Lehmann, R. B. LaPrairie, A. M. Szczesniak, J. Zhou, E.M. Denovan-Wright, & M. E. M. Kelly (2013). Anti-inflammatory effects of cannabinoid CB2 receptor activation in endotoxin-induced uveitis. *British Journal of Pharmacology*, 171, 1448-1461.

Tomida, Ileana, Augusto Azuara-Blanco, Heather House, Maggie Flint, Roger G. Pertwee, & Philip J. Robson (2006). Effects of sublingual application of cannabinoids on intraocular pressure: a pilot study. Journal of *Glaucoma*, 23, 349-353.

Tomida, I., R. G. Pertwee, & A. Azuara-Blanco (2004). Cannabinoids and glaucoma. *British Journal of Ophthalmology*, 88, 708-713.

Yang, H., Z. Wang, J. E. Capó-Aponte, F. Zhang, Z. Pan, & P. S. Reinach (2010). Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. *Experimental Eye Research*, 91, 462-471.

Yazulla, Stephen (2008). Endocannabinoids in the retina: From marijuana to neuroprotection. *Progress in Retinal and Eye Research*, 27, 501-526.

Zabouri, N., J.-F. Bouchard, & C. Casanova. (2011). Cannabinoid receptor type 1 expression during postnatal development of the rat retina. *The Journal of Comparative Neurology*, 5(19), 1258-1280.

Chapter II: Neurological Health and Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the neurological system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the neurological system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the neurological system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for neurological disorders.

The Endocannabinoid System and THC and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System: **Cerebral Endocannabinoid Network**
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control, and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors.

Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems, as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, HIV has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as acquired, originating from an infectious source. The presentation of multiple sclerosis in HIV/AIDS, which affects the neurological system, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the neurological system, which is directly affected by the immunological. Indeed, research supports that plant-derived cannabidiol (CBD) has neuroprotective benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of oxidative neurological disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects that are beneficial in the prevention and management of certain neurological disorders.

Human Brain
The brain is the core governing structure of the human body. At a weight of over three pounds, the human brain, comprised of eighty-six billion neurons and associated glial cells and blood vessels, is the largest and most complex of all mammalian brains. The human cerebral cortex, a thick layer of neural tissue, is divided into four lobes of the forebrain; the frontal, parietal, temporal, and occipital lobes. Each lobe is comprised of cortical areas associated with particular executive functions, including self-control, planning, reasoning, abstract thought, motor control, language, and vision. The two hemispheres of the brain are defined by lateralization processes, such as language, which is associated with left-sided hemispheric dominance, and spatiotemporal reasoning, which is associated with right-sided dominance. The cerebellum, or hindbrain, located at the base of the brain above the brainstem, coordinates voluntary movements such as posture, balance, coordination, speech, and learned motor behaviors. Further, the brainstem, which includes the medulla oblongata, pons, and the midbrain, regulates motor and sensory aspects of the central nervous system, as well as cardiac and respiratory functions. Finally, the endocannabinoid system, comprised of neuromodulatory lipids and receptors in the brain, regulates the vast array of physiological processes essential for human life.

Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease, is a neurodegenerative disorder characterized by muscle spasticity, rapid and progressive weakness, muscle wasting,

dysphagia, expressive aphasia, and respiratory failure. Endocannabinoid deficiency (CECD), noted as genetic and acquired in ALS, has been documented, and is characterized by decreased cannabinoid availability and subsequent decline in the number of CB1 receptors. CB1 receptors are critical in the cerebral cortex and are responsible in reducing TAU protein proliferation. Further, CB2 receptors are also rendered dysfunctional in ALS, causing expedited inflammatory responses, which correlate with the aggressive clinical neurological decline in affected individuals. Research supports the administration of cannabidiol (CBD) preventatively for neuroprotection in individuals with hereditary risk factors, and post-diagnosis, to decrease neuroinflammation, reduce neurodegeneration, and increase cerebral plasticity. Because cannabidiol (CBD) has an analgesic and antispasmodic effect, administration of cannabidiol (CBD) is supported by clinical research in the adjunctive management of spasm and associated pain in ALS.

Recently, THC has been evaluated for relief of specific symptoms of ALS, including pain, spasticity, dysphagia, and speech impairment. Case studies indicate low doses of THC with CBD oil warrant consideration in the medical management of individual patients.

Alzheimer's Disease
Alzheimer's disease is a progressive neurodegenerative disorder, which affects the cerebral neurons causing loss of memory, language and cognitive abilities, and mood and behavioral changes. The death of neurons that normally produce acetylcholine, the neurotransmitter that facilitates communication within brain, characterizes a progressive neurological deterioration. Hippocampal nerve cells are initially affected causing short-term memory decline. With progression to the cerebral cortex, the decline of language skills and the impairment of judgment are clinically noted. The endocannabinoid deficiency (CECD), which characterizes Alzheimer's, is categorized as both genetic and idiopathic autoimmune. Aggregation of amyloid-beta tau proteins and profound neurodegeneration, neuroinflammation, and neurotoxicity, which characterize Alzheimer's, were induced in animal models. Reversal of social recognition dysfunction and anxiety was demonstrated after the administration of cannabidiol (CBD), a non-psychoactive phytocannabinoid that exhibits neuroprotective, anti-inflammatory, and anti-oxidant properties, and promotes neurogenesis in the brain. Further research supports using cannabidiol (CBD) with THC as a preventive measure against Alzheimer's, noting the anti-inflammatory and neuroprotective properties of CBD. Thus, cannabidiol (CBD) in combination with THC can be useful after diagnosis, and proactively, in the management of Alzheimer's disease.

Parkinson's Disease
In Parkinson's disease, which affects the substantia nigra in the midbrain, the production of dopamine, and the basal ganglia, progressive symptoms including bradykinesia, muscle and joint stiffness, impaired balance, dysphasia, impaired reaction time, memory, sleep disturbances, depression, and anxiety, are associated with endocannabinoid deficiency (CECD) of genetic origin. Research indicates that the administration of cannabidiol (CBD) with low dose THC reduced dystonia, spasticity, and phytocannabinoid administration. Research indicates a positive human response to adjunctive use of cannabidiol (CBD) with low dose THC in the management of dystonia, tremor, psychosis, spasticity, and associated neuropathic pain. Because cannabidiol (CBD) exhibits neuroprotective and anti-inflammatory properties,

administration is recommended prophylactically in individuals at genetic risk for disease development to preserve neuronal integrity and CB1 and CB2 receptor functionality in the cerebral cortex.

Huntington's Chorea

Huntington's chorea, a progressive neurodegenerative disorder, which affects motor coordination, causes involuntary movement patterns, cognitive and psychiatric decline, and behavioral abnormalities, is categorized as a disease associated with genetic endocannabinoid deficiency (CECD). In Huntington's chorea, CB1 receptors in the basal ganglia are significantly reduced, which affects the upregulatory responses of the CB2 receptors in lesioned areas. Cannabinoids, which normally provide neuroprotection, are progressively diminished in Huntington's chorea, which accounts for the neuronal destruction throughout the cerebral cortex and associated symptomatology, including painful dystonic movements, anxiety, and depression. Cannabidiol (CBD) with low dose THC has been demonstrated to slow progressive dystonic symptoms and associated pain, relieve anxiety, and enhance well-being in patients affected by the disease. In individuals at genetic predisposition for the development of Huntington's chorea, the neuroprotective effects of cannabidiol (CBD) may slow the onset and severity of symptoms associated with Huntington's chorea.

Cerebral Ischemia and Stroke

Cerebral ischemia refers to injury to the cerebral cortex as a result of an obstruction within the circulatory system of the brain. Factors that contribute to cerebral ischemia and stroke include atherosclerosis, hypertension, diabetes, and nicotine use. Cerebral thrombosis, or cerebral embolism, interrupts cerebral blood flow, resulting in paralysis, expressive and receptive aphasia, and/or death. The acquired endocannabinoid system deficiency (CECD), which precedes cerebral ischemia and cerebral stroke, reflects forebrain CB1 and CB2 receptor dysfunction and diminished circulating cannabinoids. Indeed, immediate administration of cannabidiol (CBD) up to four hours after a cerebral ischemic incident reduced inflammatory and residual motor deficits in human subjects. The antioxidant, anxiolytic, and neuroprotective properties of cannabidiol (CBD) with low dose THC were also found to be preventative in subjects predisposed to cerebral ischemia, enhancing cerebral function through restoration of circulating cannabinoids and functionality of CB1 and CB2 receptors.

Multiple Sclerosis

Multiple sclerosis is a neurodegenerative disorder characterized by the production of lesions in the cerebral cortex and spinal cord and diminished myelin cell production. Classified as remitting-relapsing, in which exacerbations with residual deficits and recovery spanning over years, or progressive, which alludes to a downward spiral of neurological deterioration following diagnosis, until death, multiple sclerosis affects such functions as motor coordination, cognition, and thermoregulation. The endocannabinoid system deficiency (CECD) in multiple sclerosis is idiopathic autoimmune, and sensory pathways are affected as myelin sheath destruction occurs. Pain and spasticity affect nearly all patients with multiple sclerosis. Cannabidiol (CBD), with low dose THC, which has neuroprotective and analgesic affects, effectively reduces pain and spasticity associated with multiple sclerosis. Administration of cannabidiol (CBD) early in the diagnosis of multiple sclerosis is suggested to reduce the neuroinflammatory response within the cerebral

cortex, enhance cannabinoid binding to CB1 and CB2 receptors, and reduce potential myelin cell destruction.

Schizophrenia

Schizophrenia is a psychiatric disorder characterized by abnormal social behavior, inability to discern reality from fantasy, confused thought processes, hallucinations, limited social interactions and emotional expression, and inactivity. Research indicates that circulating cannabinoids in the forebrain are depleted and CB1 receptors become less dense, causing decrease receptivity. The endocannabinoid deficiency (CECD) in schizophrenia appears to be genetic and pharmacological approaches, which have focused upon the antagonism of dopamine receptors, have been of limited value. The administration of cannabidiol (CBD) has been shown to increase the density of CB1 receptors and increase available cannabinoids in the brain. Anxiety, hallucinations, and behavioral modification have been noted, warranting concurrent administration of cannabidiol (CBD) in the management of schizophrenia.

Epilepsy

Dravet syndrome or Severe Myoclonic Epilepsy of Infancy (SMEI), is form of irretractable epilepsy, which emerges in infancy with prolonged and frequent seizure activity. Behavioral and developmental delays, motor development and coordination, language and speech acquisition, growth and nutritional deficiencies, immunosuppression, sensory integration disorders, and autonomic nervous system dysregulation characterize this disorder. Sudden unexplained death in epilepsy is prevalent as well. Endocannabinoid deficiency (CECD) is categorized as idiopathic autoimmune in light of the decrease in circulating cannabinoids and the reduced density of both CB1 and CB2 receptors. Research has conclusively demonstrated the benefit of the administration of cannabidiol (CBD) in Dravet syndrome - reducing persistent seizure activity in the majority of human subjects, reducing associated symptoms, and improving cognitive function. Increased cannabinoid availability and increased density of CB1 and CB2 receptors correlates with neurological improvement in Dravet, supporting the possible concurrent and preventative use of cannabidiol (CBD) in other forms of epileptic disorders.

Migraine

Migraine is a chronic neurological disorder characterized by moderate to severe headaches accompanied by autonomic nervous symptoms, including nausea and vomiting, light, sound, and smell sensitivities, and pain. Approximately one-third of individuals present with an aura, or transient visual, auditory, sensory, linguistic, or motor disturbance prior to migraine onset. Endocannabinoid deficiency (CECD) in migraine is categorized as genetic, with statistically significant hereditary prevalence. CB1 receptors in the cerebral cortex and trigeminal nucleus of the brainstem appear unable to process neurotransmitters, causing inflammatory responses, which induce severe pain. Cannabidiol (CBD) is suggested to reduce neurovascular inflammation and provide analgesia in migraine and prophylaxis in chronic migraine.

Cancer of the Brain

Malignancy in the human brain can be the primary source of the respective cancer or secondary metastasis from a primary site. The anticarcinogenic effects of cannabidiol (CBD) and THC in certain types of cancer are well documented. Gliomas and brain metastasis from breast and lung cancer are potential targets for cannabidiol (CBD) therapy. Cannabinoids

produce antitumor effects through induction of cell death, cell growth inhibition, and inhibition of tumor angiogenesis. Endocannabinoid deficiency (CECD) in oncology is categorized as genetic and/or acquired and responds to administration of concentrated cannabidiol (CBD) and THC. Neuroprotection of non-transformed cells has also been demonstrated, suggesting adjunctive cannabidiol (CBD) with combination THC therapy when chemotherapy and/or radiation are also recommended.

Depression & Anxiety
Major affective mood disorders, including depression and anxiety, are targets for cannabidiol (CBD) therapy. Depression, which is characterized by pervasive and persistent low mood, low self-esteem, and loss of interest in normally enjoyable activities, affects CB1 receptors in such areas as the anterior cingulate cortex and the subgenual cingulate. Neurodegeneration of the ventricles is also noted in chronic depression, highlighting CB2 receptor dysregulation as well. In anxiety disorders, CB1 receptors in the amygdala, which elicits the fight or flight response, and in the anterior cingulate cortex, are affected. Excessive and persistent worry characterizes this disorder. Both depression and anxiety are categorized as either genetic or acquired endocannabinoid deficiencies (CECD), which respond to the administration of cannabidiol (CBD). The anxiolytic and antidepressant properties of cannabidiol (CBD) increase available circulating cannabinoids to affected cerebral areas in both disorders and enhance receptivity of dysfunctional CB1 and CB2 receptors.

Chronic Traumatic Encephalopathy (CTE)
Chronic traumatic encephalopathy (CTE) is associated with repetitive concussion to the brain, tau protein expression, neurodegeneration, mood disorders, including rage and depression, and dementia. CTE in football, basketball, boxing, and soccer, and among combat military personnel, affects the endocannabinoid system as an acquired deficiency. Depending upon the area of traumatic injury, regional CB1 and CB2 receptors are affected. Available cannabinoids decline in CTE, affecting serotonin and dopamine responses, neurotransmitter communication, and the density of CB1 and CB2 receptors. Administration of cannabidiol (CBD) with low dose THC after the development of CTE has demonstrated a positive response, with reduction in symptomatology. Preventative THC with cannabidiol (CBD) administration is recommended for individuals at risk for CTE because cannabidiol (CBD) and low dose THC reduce neuroinflammatory responses, are anxiolytic, thereby reducing cell death, and are restorative in the functionality of affected CB1 and CB2 receptors.

Endocannabinoid Deficiency (CECD) Classification: Neurological Disorders

Disorder	Origin of CECD
ALS	Genetic, Acquired
Alzheimer's	Genetic
Parkinson's	Genetic
Huntington's Chorea	Genetic
Cerebral Ischemia and Stroke	Genetic, Acquired
Multiple Sclerosis	Idiopathic Autoimmune
Epilepsy and Dravet's	Genetic
Migraine	Genetic, Acquired
Depression, Anxiety	Genetic, Acquired
CTE	Acquired

CEN Medical Cannabis Pharmacological Prescription and Coding System
Neurological Disorder Application

The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: THC is recommended for the patient for Chronic Traumatic Encephalopathy (CTE), (ICD-9: 363.20). The prescription would therefore read:

Marvin James Reynolds
Date of Birth: 09-01-1989
Diagnosis: Chronic Traumatic Encephalopathy (CTE), ICD-9 code:
CS: 14-19%/ 6-8%. Use cannabis sativa every 6 hours as needed via vaporizer.
Margaret Henderson, M.D.

The patient would then be able to purchase the cannabis sativa at a dispensary, offering the prescription to the pharmacist or technician.

Composition Assignments
1. Please answer the following question: Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with migraines.
    a. True
    b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the neurological system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
    a. Author and affiliation
    b. Study population
    c. Purpose
    d. Outcome of the study
    e. Importance of the research

Bibliography

Abrams, D. I., C. A. Jay, S. B. Shade, H. Vizoso, H. Reda, S. Press, M. E. Kelly, M. C. Rowbotham, & K. L. Petersen (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*, 68, 516-521.

Bakheit, Abdel Magid O. (2012). The pharmacological management of post-stroke muscle spasticity. *Drugs Aging*, 29, 941-947.

Barichello, Tatiana, Renan A. Ceretta, Jacqueline S. Generoso, Ana Paula Moreira, Lutiana R. Simões, Clarissa M. Comim, João Quevedo, Márcia Carvalho Vilela, Antonio Waldo Zuardi, José A. Crippa, & Antônio Lucio Teixeira (2012). Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. *European Journal of Pharmacology*, 697, 158-164.

Basavarajappa, Balapal S. (2007). Neuropharmacology of the endocannabinoid signaling mechanisms, biological actions and synaptic plasticity. *Current Neuropharmacology*, 5, 81-97.

Berman, Jonathan S., Catherine Symonds, & Rolfe Birch (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. *Pain*, 112, 299-306.

Bilsland, Lynsey G., James R. Dick, Gareth Pryce, Stefania Petrosino, Vincenzo di Marzo, David Baker, & Linda Greensmith (2006). Increasing cannabinoid levels by pharmacological genetic manipulation delays disease progression in SOD1 mice. *The Federation of American Societies for Experimental Biology*, 20, 1004-1018.

Bologov, Anastasia, Mikhal Gafni, Ora Keren, & Yosef Sarne (2011). Dual protective and neurotoxic effects of cannabinoid drugs in vitro. *Cellular and Molecular Neurobiology*, 31, 195-202.

Bonn-Miller, Marcel O., Kimberly A. Babson, & Ryan Vandrey (2014). Using cannabis to help you sleep: heightened frequency of medical of medical cannabis use among those with PTSD. *Drug and Alcohol Dependence*, 136, 162-165.

Booz, George W. (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. *Free Radical Biology and Medicine*, 51(5), 1054-1061.

Bossong, Matthijs G., J. Martin Jansma, Sagnik Bhattacharyya, & Nick F. Ramsey (2014). Role of the endocannabinoid system in brain function relevant for schizophrenia: an overview of human challenge studies with cannabis or Δ9-tetrahydrocannabinol (THC). *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 52, 53-69.

Bragg, Raphael J., Katherine E. Burdick, Pamela DeRosse, & Anil Malhotra (2012). Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. *Psychiatry Research*, 200, 242-245.

Braida, Daniela, Simona Pegorini, Maria Vittoria Arcidiacono, Gian Giacomo Consalez, Laura Croci, & Mariaelvina Sala (2003). Post-ischemic treatment with cannabidiol electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. *Neuroscience Letters*, 346, 61-64.

Brook, George (2008). National industrial hemp strategy. Manitoba Agriculture, Food and Rural Initiative Agriculture and Agri-Food Canada, 1-348.

Buczynski, Matthew W. & Loren H. Parsons (2010). Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. *British Journal of Pharmacology*, 160, 423-442.

Cabral, G. A., E. S. Raborn, L. Griffin, J. Dennis, & F. Marciano-Cabral (2008). CB2 receptors in the brain: role in central immune function. *British Journal of Pharmacology*, 153, 240-251.

Capettini, Luciano S. A., Silvia Q. Savergnini, Rafaela F. da Silva, Nikos Stergiopulos, Robson A. S. Santos, François Mach, & Fabrizio Montecucco (2012). Update on the role of cannabinoid receptors after ischemic stroke. *Mediators of Inflammation*, 10, 1-8.

Carter, Gregory T., Mary E. Abood, Sunil K. Aggarwal, & Machael D. Weiss (2010). Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. *American Journal of Hospice and Palliative Medicine*, 27(5), 347-356.

Chen, Jing, Kalpana S. Paudel, Andrei V. Derbenev, Bret N. Smith, & Audra L. Stinchcomb (2009). Simultaneous quantification of arandamide and other endo-cannabinoids in dorsal vagal complex in rat brainstem by LC-MS. *Chromatographia*, 69(1-2), 1-7.

Chiarlone, Anna, Luigi Bellocchio, Cristina Blazquez, Eva Resel, Edgar Soria-Gomez, Astrid Cannich, Jose J. Ferrero, Onintza Sagredo, Cristina Benito, Julian Romero, Jose Sanchez-Prieto, Beat Lutz, Javier Fernandez-Ruiz, Ismael, Galve-Roperh, & Manuel Guzman (2014). A restricted population of CB1 cannabinoid receptors with neuroprotective activity. *Proceedings of the National Academy of Sciences*, 111(22), 8257-8262.

Cilio, Maria Roberta, Elizabeth A. Thiele, & Orrin Devinsky (2014). The case for assessing cannabidiol in epilepsy. *Epilepsia*, 55(6), 787-790.

Collin, C., P. Davies, I. K. Mutiboko, & S. Ratcliffe (2007). Randomized controlled Trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *European Journal of Neurology*, 14, 290-296.

Consroe, Paul, Joan Laguna, James Allender, Stuart Snider, Lawrence Stern, Reuven Sandyk, Kurt Kennedy, & Karl Schram (1991). Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacology, Biochemistry, & Behavior*, 40,701-708.

Costa, Barbara, Anna Elisa Trovato, Francesca Comelli, Gabriella Giagnoni, & Mariapia Colleoni (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *European Journal of Pharmacology*, 556, 75-83.

Croxford, J. Ludovic (2003). Therapeutic potential of cannabinoids in CNS disease. *Adis Data Information*, 17(3), 179-202.

De Bitencourt, Rafael Mariano, Fabricio Alano Pamplona, & Reinaldo Naoto Takahashi (2013). A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. *Neuropharmacology*, 64, 389-395.

De la Ossa, Dolores Hernán, Mar Lorente, Maria Esther Gil-Alegre, Sofia Torres, Elena Garcia-Taboada, María del Rosario Aberturas, Jesús Molpeceres, Guillermo Velasco, Ana Isabel Torres-Suárez (2013). Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. *PLOS One*, 8(1), 1-8.

Deiana, Serena (2012). Medical use of cannabis. Cannabidiol: A light for schizophrenia? *Drug Testing Analysis*, 5, 46-51.

Devinsky, Orrin, Maris Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo di Marzo, Didier Justras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, & Daniel Friedman (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*, 55(6), 791-802.

Deshpande, Laxmikant, Robert E. Blair, Julie M. Ziobro, Sompong Sombati, Billy R. Martin, & Robert J. DeLorenzo (2007). Endocannabinoids block status epilepticus in cultured hippocampal neurons. *European Journal of Pharmacology*, 558(1-3), 52-59.

Di Iorio, Giuseppe, Marreo Lupi, Fabiola Sarchione, Ilaria Matarazzo, Rita Santacroce, Filippo Petruccelli, Giovanni Martinotti, & Massimo di Giannantonio (2013). The endocannabinoid system: a putative role in neurodegenerative diseases. *International Journal of High Risk Behavoir and Addiction*, 2(3), 100-106.

DiPatrizio, Nicholas V. & Daniele Piomelli (2012). The thrifty lipids: Endocannabinoids and the neural control of energy conservation. *Trends in Neuroscience*, 35(7), 403-411.

Dirikoc, Sevda, Suzette A. Priola, Mathieu Marella, Nicole Zsürger. & Joëlle Chabry (2007). Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. *Neurobiology of Disease*, 27 (36), 9537-9544.

Do Monte, Francis H., Rimenez R. Souza, Rafael Bitencourt, & Juliana A. Kroon (2013). Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors. *Behavioural Brain Research*, 250, 23-27.

Dowie, Megan J., Natasha L. Grimsey, Therri Hoffman, Richard L. M. Faull, & Michele Glass (2014). Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. *Journal of Chemical Neuroanatomy*, 59/60, 62-71.

El-Alfy, Abir T., Kelly Ivey, Keisha Robinson, Safwat Ahmed, Mohamed Radwan, Desmond Slade, Ikhlas Khan, Mahmoud ElSohly, & Samir Ross (2010). antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from *Cannabis sativa* L. *Pharmacology, Biochemistry and Behavior*, 95, 434-442.

Elphick, Maurice R. (2012). The evolution and comparative neurobiology of endocannabinoid signaling. *Philosophical Transactions of the Royal Society*, 367, 3201-3215.

Espejo-Porras, Francisco, Javier Fernández-Ruiz, Roger G. Pertwee, Raphael Mechoulam, Concepción García (2013). Motor effects of the non-psychotropic phytocannabinoid cannabidiol that a.re mediated by 5-HT(1a) receptors. *Neuropharmacology*, 75, 155-163.

Esposito, Giuseppe, Daniele de Filippis, Rosa Carnuccio, Angelo A. Izzo, & Teresa Iuvone (2005). The marijuana component cannabidiol inhibits beta-amyloid induced tau protein hyperphosphoralation through Wnt/beta-catenin pathway rescue in PC 12 cells. *Journal of Molecular Medicine*, 8(4), 253-258.

Esposito, Giuseppe, Daniele de Filippis, Luca Steardo, Caterina Scuderi, Claudia Savani, Vincenzo Cuomo, & Teresa Iuvone (2006). CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. *Neuroscience Letters*, 404, 342-346.

Esposito, G. C. Scuderi, C. Savani, L. Steardo, Jr., D. de Filippis, P. Cottone, T. Luvone, V. Cuomo, & L. Steardo (2007). Cannabidiol *in vivo* blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. *British Journal of Pharmacology*, 151, 1272-1279.

Esposito, Giuseppe, Caterina Scuderi, Marta Valentina, Giuseppina Ines Togna, Valentina Latina, Daniele de Filippis, Mariateresa Cipriano, Maria Rosaria Carratu, Teresa Iuvone, & Luca Steardo (2011). Cannabidiol reduces alphabeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. *PLOS One*, 6(11), 1-8.

Eubanks, Lisa M., Claude J. Rogers, Albert E. Beuscher, IV, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, & Kim D. Janda (2006). A molecular link between the active component of marijuana and alzheimer's disease pathology. *Molecular Pharmaceuticals*, 3(6), 773-777.

Fernández-Ruiz, Javier, Miguel Moreno-Martet, Carmen Rodríguez-Cueto, Cristina Palomo-Garo, María Gómez-Cañas, Sara Valdeolivas, Carmen Guaza, Julián Romero, Manuel Guzmán, Raphael Mechoulam, & José A. Ramos (2011). Prospects for cannabinoid Therapies in basal ganglia disorders. *British Journal of Pharmacology*, 163, 1365-1378.

Fujii, Mutsumi, Prativa Sherchan, Paul R. Krafft, William B. Rolland, Yoshiteru Soejima, & John H. Zhang (2014). Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. *Journal of Neurological Sciences*, 342, 101-106.

García-Arencibia, Moisés, Sara González, Eva de Lago, José A. Ramos, Raphael Mechoulam, Javier Fernández-Ruiz (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidants and cannabinoid receptor-independent properties. *Brain Research*, 1134, 162-170.

Gates, Peter J., Lucy Albertella, & Jan Copeland (2014). The effects of cannabinoid administration on sleep: a systematic review of human studies. *Sleep Medicine Reviews* (article in press), 1-22.

Gloss, D. & B. Vickrey (2014). Cannabinoids for epilepsy. *The Cochrane Collaboration*, 3, 1-23.

Grotenhermen, Franjo (2006). Cannabinoids and the endocannabinoid system. *Cannabinoids*, 1(1), 10-14.

Grotenhermen, Franjo & Gero Leson (2003). Reassessing the drug potential of industrial hemp. *Drug Potential of Fibre Hemp*, 1-48.

Grundy, Robert I., Monica Rabuffetti, & Massimiliano Beltramo (2001). Cannabinoids and neuroprotection. *Molecular Neurobiology*, 24, 29-51.

Guiterrez, Tannia & Andrea G. Hohmann (2011). Cannabinoids for the treatment of neuropathic pain: are they safe and effective? *Future Neurology*, 6(2), 129-133.

Hampson, A. J., M. Grimaldi, M. Lolic, D. Wink, R. Rosenthal, & J. Axelrod (1998). Neuroprotective antioxidants from marijuana. *Annals of the New York Academy of Science*, 274-282.

Haney, Margaret, Erik W. Gunderson, Judith Rabkin, Carl L. Hart, Suzanne K. Vosburg, Sandra D. Comer, & Richard W. Foltin (2007). Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep. *Journal of Acquired Immune Deficiency Syndrome*, 45(5), 545-554.

Harvey, Benjamin S., Katharina S. Ohlsson, Jesper L. V. Mååg, Ian F. Musgrave, Scott D. Smid (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-B evoked neurotoxicity in vitro. *Neurotoxicology*, 33, 138-146.

Hayakawa, Kazuhide, Kenichi Mishima, Keiichi Irie, Mai Hazekawa, Shohei Mishima, Masayuki Fujioka, Kensuke Orito, Nobuaki Egashira, Shutaro Katsurabayashi, Kotaro Takahaski, Katsunori Iwasaki, & Michihiro Fujiwara (2008). Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. *Neuropharmacology*, 55, 1280-1286.

Hayakawa, Kazuhide, Kenichi Mishima, Masanori Nozako, Mai Hazekawa, Keiichi Irie, Masayuki Fujioka, Kensuke Orito, Kohji Abe, Nobuyoshi Hasebe, Nobuaki Egashira, Katsunori Iwasaki, & Michihiro Fujiwara (2007). Delayed treatment with cannabidiol has a cerbroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. *Journal of Neurochemistry*, 102, 1488-1496.

Hayakawa, Kazuhide, Kenichi Mishima, Masanori Nozako, Ayumi Ogata, Mai Hazekawa, An-Xin Liu, Masayuki Fukioka, Kohji Abe, Nobuaki Egashira, Katsunori Iwasaki, & Michihiro Fujiwara (2007). Repeated treatment with cannabidiol but not tetrahydro-cannabidiol has a neuroprotective effect without the development of tolerance. *Neuropharmacology*, 52, 1079-1087.

Hayakawa, Kazuhide, Kenichi Mishima, & Michihiro Fujiwara (2010). Therapeutic potential of non-psychotropic cannabidiol in ischemic stroke. *Pharmaceuticals*, 3, 2197-2212.

Hebert-Chatelain, Etienne, Leire Reguero, Nagore Puente, Beat Lutz, Francis Chaouloff, Rodrigue Rossignol, Pier-Vincenzo Piazza, Giovanni Benard, Pedro Grandes, & Giovanni Marsicano (2014). Cannabinoid control of brain bioenergetics: exploring the subcellular localization of the CB1 receptor. *Molecular Metabolism*, 3(4), 495-504.

Herkenham, Miles (1989). Cannabinoid receptor localization in brain: relationship to motor and reward systems. *Annals of the New York Academy of Sciences*, 19-32.

Hill, Andrew J., Claire M. Williams, Benjamin J. Whalley, & Gary J. Stephens (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. *Pharmacology & Therapeutics*, 133, 79-97.

Hofmann, Mackenzie E. & Charles J. Frazier (2013). Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention. *Experimental Neurology*, 244, 43-50.

Hwang, Jeannie, Crista Adamson, David Butler, David R. Janero, Alexandros Maktiyannis, & Ben A. Bahr (2010). Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. *Life Sciences*, 86, 615-623.

Iring, András, Éva Ruisanchez, Miriam Leszl-Ishiguro, Belá Horváth, Rita Benkö, Zsombor Lacza, Zoltán Járai, Péter Sándor, Vincenzo Di Marzo, Pál Pacher, & Zoltán, Benyó (2013). Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. *PLOS One*, 8(1), 1-11.

Iuvone, Teresa, Giuseppe Esposito, Ramona Esposito, Rita Santamaria, Massimo di Rosa, &

Angelo A. Izzo (2004). Neuroprotective effect of cannabidiol, a non-psychactive component from *Cannabis sativa*, on beta-amyloid induced toxicity in PC 12 cells. *Journal of Neurochemistry*, 89, 134-141.

Jiang, Wen, Yun Zhang, Lan Xiao, Jamie van Cleemput, Shao-Ping Ji, Guang Bai, & Xia Zhang(2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. *The Journal of Clinical Investigation*, 115(11), 3104-3106.

Jones, Nicholas A., Sarah E. Glyn, Satoshi Akiyama, Thomas D. M. Hill, Andrew J. Hill, Samantha E. Weston, Mathew D. A. Burnett, Yuki Yamasaki, Gary J. Stephens, Benjamin J. Whalley, & Claire M. Williams (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. *Seizure*, 21, 344-352.

Katona, István & Tamás F. Freund (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. *Nature Medicine*, 14(9), 923-930.

Kim, Hee Jung, Angela H. Shin, & Stanley A. Thayer (2011). Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp 120-induced synapse loss. *Molecular Pharmacology*, 80(3), 357-366.

Kouri, Naomi, Kenichi Oshima, Makio Takahashi, Melissa E. Murray, Zeshan Ahmed, Joseph E. Parisi, Sho-Hui C. Yen, & Dennis W. Dickson (2013). Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. *Acta Neuropathologia*, 125, 741-752.

Krishnan, S., R. Cairns, & R. Howard (2009). Cannabinoids for the treatment of dementia (review). *The Cochrane Collaboration*, 1-20.

Lafenêtre, Pauline, Francis Chaouloff, & Giovanni Marsicano (2007). The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear and extinction. *Pharmacological Research*, 56, 367-381.

Lara-Celador, Idoia, Lourdes Castro-Ortega, Antonia Álvarez, Felipe Goñi-de-Cerio, Jaione Lacalle, & Enrique Hilario (2012). Endocannabinoids reduce cerebral damage after hypoxic-ischemic injury in perinatal rats. *Brain Research*, 1474, 91-99.

Lemos, José Inácio, Leonardo Barbosa Resstel, & Francisco Silveira Guimarães (2010). Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. *Behavioural Brain Research*, 207, 105-111.

Liang, Caihua, Michael D. McClean, & Carmen Marsit (2009). A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. *Cancer Prevention Research*, 2, 759-768.

Liu, Qing, Manjunatha Bhat, Wayne D. Bowen, & Jianguo Cheng (2009). Signaling pathways from cannabinoid receptor-1 activation to inhibition of *N*-methyl-d-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. *The Journal of Pharmacology and Experimental Therapeutics*, 331(3), 1062-1070.

Lotan, Itay, Therese A. Treves, Yaniv Roditi, & Ruth Djaldetti (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. *Clinical Neuropharmacology*, 37, 41-44.

Maa, Edward and Paige Figi (2014). The case for medical marijuana in epilepsy. *Epilepsia*, 55(6), 783-786.

Maccarrone, M., G. Bernardi, A. Finazzi Agro, & D. Centonze (2011). Cannabinoid receptor Signaling in neurodegenerative diseases: a potential role for membrane fluidity Disturbance. *British Journal of Pharmacology*, 163, 1379-1390.

Marchalant, Yannick, Kevin Baranger, Gary L. Wenk, Michel Khrestchatisky, & Santiago Rivera (2012). Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? *Journal of Neuroinflammation*, 9(10), 1-3.

Martin-Moreno, Ana María, Begoña Brera, Carlos Spuch, Eva Carro, Luis García-Garcia, Mercedes Delgado, Miguel A. Pozo, Nadia G. Innamorato, Antonio Cuadrado, & María L. de Ceballos (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. *Journal of Neuroinflammation*, 9(8), 1-15.

Mathern, Gary, Astrid Nehlig, & Michael Sperling (2014). Cannabidiol and medical marijuana for the treatment of epilepsy. *Epilepsia*, 55(6), 781-782.

McGeeney, Brian F. (2012). Cannabinoids and hallucinogens for headache. Headache: The Journal of Head and Face Pain, 53(3), 447-458.

McKee, Ann C., Robert C. Cantu, Christopher J. Nowinski, E. Tessa Hedley-Whyte, Brandon E. Gavett, Andrew E. Budson, Veronica E. Santini, Hyo-Soon Lee, Caroline A. Kubilus, & Robert A. Stern (2009). Chronic traumatic encephalopathy in athletes: Progressive tauopathy following repetitive head injury. *Journal of Neuropathology and Experimental Neurology*, 68(7), 709-735.

Mckee, Ann C., Brandon E. Gavett, Robert A. Stern, Christopher J. Nowinski, Robert C. Cantu, Neil W. Kowall, Daniel P. Perl, E. Tessa Hedley-Whyte, Bruce Price, Chris Sullivan, Peter Morin, Hyo-Soon Lee, Caroline A. Kubilus, Daniel H. Daneshvar, Megan Wulff, & Andrew E. Budson (2010). TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. *Journal of Neuropathology and Experimental Neurology*, 69(9), 918-929.

McKee, Ann C., Thor D. Stein, Christopher J. Nowinski, Robert A. Stern, Daniel H. Daneshvar, Victor E. Alvarez, Hyo-Soon Lee, Garth Hall, Sydney M. Wojtowicz, Christine M. Baugh, David O. Riley, Caroline A. Kubilus, Kerry A. Cormier, Matthew A. Jacobs, Brett R. Martin, Carmela R. Abraham, Tsuneya Ikezu, Robert Ross Reichard, Benjamin L. Wolozin, Andrew E. Budson, Lee E. Goldstein, Neil W. Kowall, & Robert C. Cantu (2013). The spectrum of disease in chronic traumatic encephalopathy. *Brain*, 136, 43-46.

Mechoulam, R. (2002) Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 66(2/3),93-99.

Meisel, Karl & Joseph H. Friedman (2012). Medical marijuana in Huntington's disease: report of two cases. *Medicine and Health*, 95, 178-179.

Micale, Vincenzo, Vincenzo di Marzo, Alexandra Sulcova, Carsten T. Wotjak, & Filippo Drago (2013). Endocannabinoid system and mood disorders: Priming a target for new therapies. *Pharmacology & Therapeutics*, 138, 18-37.

Morena, Maria & Patrizia Campolongo (2014). The endocannabinoid system: An emotional buffer in the modulation of memory function. *Neurobiology of Learning and Memory*, 112, 30-43.

Mulder, Jan, Misha Zilberter, Susana J. Pasquare, Alan Alpar, Gunnar Schulte, Samira G. Ferreira, Attila Kofalvi, Ana M. Martin-Moreno, Erik Kelmperna, Heikid Tanila, Masahiko Watanabe, Ken Mackie, Tibor Hortobagyl, Maria L. de Ceballos, & Tibor Harkany (2011). Molecular reorganization of endocannabinoid signaling in Alzheimer's disease. *Brain*, 134(4), 1041-1060.

Müller-Vahl, Kirsten R. (2013). Treatment of Tourette syndrome with cannabinoids. *Behavioural Neurology*, 27, 119-124.

Napchan, Uri, Dawn C. Buse, & Elizabeth W. Loder (2011). The use of marijuana or synthetic cannabinoids for the treatment of headache. Headache: The Journal of Head & Face Pain, 502-505.

Novotna, A., J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, C. Gasperini, Montalban, A. Klimek, P. Davies, & the Sativex Spasticity Study Group (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *European Journal of Neurology*, 18, 1122-1131.

Nurmikko, T. J et al. (2008). Sativex® improves pain control in patients with unresponsive and persistent neuropathic pain. *Pain*, 133, 210-220.

Ooms, Martin, Roma Rietjens, Janaki Raman Rangarajan, Kathleen Vunckx, Sara Valdeolivas, Frederik Maes, Uwe Himmelreich, Javier Fernandez-Ruiz, Guy Bormans, Koen van Laere, & Cindy Casteels (2014). Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice (article in press). *Neurobiology of Aging*, 1-12.

Pazos, M. R., V. Cinquina, A, Gómez, R. Layunta, M. Santos, J. Fernádez-Ruiz, & José Martinez-Orgado (2012). Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. *Neuropharmacology*, 63, 776-783.

Pope, C., R. Mechoulam, & L. Parsons (2010). Endocannabinoid signaling in neurotoxicity and neuroprotection. *Neurotoxicology,* 31(5), 562-571.

Price, Theodore J., Amol Patwardhan, Armen N. Akopian, Kenneth M. Hargreaves, & Christopher M. Flores (2004). Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. *British Journal of Pharmacology*, 141, 118-1130.

Ramírez, Beléz G., Cristina Blázquez, Teresa Gómez del Pulgar, Manuel Guzmán, & Maria L. de Ceballos (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *The Journal of Neuroscience*, 25(8), 1904-1913.

Ramirez, Servio H., Janoa Hasko, Andrew Skuba, Shongshan Fan, Ryan McCormick, Holly Dykstra, Nancy Reichenbach, Istvan Krizbal, Anu Mahadevan, Ming Zhang, Ronald Tuma, Young-Jin Son, & Yuri Persidsky (2012). Activation of the cannabinoid 2 receptor attenuates leukocyte-endothelial interactions and blood-brain barrier dysfunction under inflammatory conditions. *Journal of Neuroscience*, 32(12), 4004-4016.

Rezapour-firouzi, Soheila, Seyed Rafie Arefhosseini, Mehrangiz Ebrahimi-Mamaghani, Medhi Farhoudi, Behzad Baradaran, Torbati Mohammad Ali, & Fatemeh Zamani (2013). Erythrocyte membrane fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils. *African Journal of Traditional and Complementary Alternative Medicine*, 10(6), 519-527.

Rom, Slava & Yuri Persidsky (2013). Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation. *Journal of Neuroimmune Pharmacology*, 8, 608-620.

Rossi, Silvia, Giogio Bernardi, Diego Centoze (2010). The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotropic lateral sclerosis. *Experimental Neurology*, 224, 92-102.

Russo, Ethan (1998). Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. *Pain*, 76, 3-8.

Ryan, Duncan, Alison J. Drysdale, Carlos Lafourcade, Roger G. Pertwee, & Bettina Platt (2009). Cannabidiol targets mitochondria to regulate intracellular CA2+ levels. *The Journal of Neuroscience*, 29(7), 2053-2063.

Schubart, C. D., I. E. C. Sommer, P. Fusar-Poli, L. de Witte, R. S. Khan, & M. P. Boks (2014). Cannabidiol as potential treatment for psychosis. *European Neuropsychopharmacology*, 24, 51-64.

Scotter, Emma L., Mary E. Abood, & Michele Glass (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. *British Journal of Pharmacology*, 160, 480-498.

Schröder, Sven, Kathrin Beckmann, Giovanni Franconi, Gesa Meyer-Hamme, & Thomas Friedemann, Henry Johannes Greten, Matthias Rostock, & Thomas Efferth (2013). Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced neuropathy? *Evidence-Based Complementary and Alternative Medicine*, 1-53.

Shirazi-zand, Zahra, Leila Ahmad-Molaei, Fereshteh Motamedi, & Nima Naderi (2013). The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electric shock models of seizure in mice. Epilepsy & *Behavior*, 28, 1-7.

Sirven, Joseph I. (2013). Medical marijuana for epilepsy: Winds of change. *Epilepsy & Behavior*, 29, 435-436.

Skaper, Stephen D. & Vincenzo Di Marco (2012). Endocannabinoids in nervous system health and disease: the big picture in a nutshell. *Philosophical Transactions of the Royal Society*, 367, 3193-3200.

Solinas, Marta, Paola Massi, Valentina Cinquina, Marta Valenti, Daniele Bolognini, Marzia Gariboldi, Elena Monti, Tiziana Rubino, & Daniela Parolaro (2013). Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. *PLOS One*, 8(10), 1-9.

Starowicz, Katarzyna & Vincenzo di Marzo (2013). Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies? *European Journal of Pharmacology*, 716, 41-53.

Svensson, Mattias, Puran Chen, & Oscar Hammerfjord (2010). Dendritic cell regulation by cannabinoid-based drugs. *Pharmaceuticals*, 3, 2733-2750.

Toth, Cory C., Nicole M. Jedrzejewski, Connie L. Ellis, & William H. Frey, II (2010). Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type 1 diabetic peripheral neuropathic pain. *Molecular Pain*, 6, 1-22.

Valvassori, Samira S., Daniela V. Bavaresco, Giselli Scaini, Roger B. Varela, Emilio L. Streck, Marcos H. Chagas, Jaime E. C. Hallak, Antonio W. Zuardi, José A. Crippa, João Quevedo (2013). Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. *Revista Brasileira de Psiquiatria*, 35, 380-386.

Vanderová, Katerina, Evžen Růžiĝka, Viktor Voříšek, & Peter Višňovský (2004). Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. *Movement Disorders*, 19(9), 1102-1106.

Wade, Derick, Petra Makela, Philip Robson, Heather House, & Cynthia Bateman (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Multiple Sclerosis*, 10, 434-441.

Wade, Derick T., Philip Robson, Heather House, Petra Makela, & Julia Aram (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clinical Rehabilitation*, 17, 21-29.

Walter, Lisa, Allyn Franklin, Anke Witting, Christian Wade, Yiheng Xie, George Kunos, Ken Mackle, & Nephi Stella (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. *The Journal of Neuroscience*, 23(4), 1398-1405.

Wang, Huikun & Carl R. Lupica (2014). Release of endogenous cannabinoids from ventral tegmental areadopamine neurons and the modulation of synaptic processes. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 52, 24-27.

Ware, Mark A. Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, & Jean-Paul Collet (2010). Smoked cannabis for chronic neuropathic pain: a randomized, controlled trial. *Canadian Association Journal*, 182(14), E694-E701.

Wilkerson, Jenny L. & Erin D. Milligan (2011). The central role of glia in pathological pain and the potential of targeting the cannabinoid 2 receptor for pain relief. *International Scholarly Research*, 1-19.

Wilsey, Barth, Thomas Marcotte, Alexander Tsodikov, Jeanna Millman, Heather Bentley, Ben Gouaux, & Scott Fishman (2008). A \randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *The Journal of Pain*, 9(6), 506-521.

Wilsey, Barth, Thomas Marcotte, Reena Deutsch, Ben Gouaux, Staci Sakai, & Haylee Donaghe (2013). Low-dose vaporized cannabis significantly improve neuropathic pain. *The Journal of Pain*, 14(2), 136-148.

Witting, Anke, Patrick Weydt, Soyon Hong, Michel Kliot, Thomas Moser, & Nephi Stella (2004). Endocannabinoids accumulate in spinal cord of SOD1 transgenic mice. *Journal of Neurochemistry*, 89, 1555-1557.

Yiangou, Yiangos, Paul Facer, Pascal Durrenberger, Iain P. Chessell, Alan Naylor, Chas Bountra, Richard R. Banati, & Praveen Anand (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. *Bio Med Central*, 6(12), 1-14.

Zajicek, J. P., H. P. Sanders, D. E. Wright, P. J. Vickery, W. M. Ingrams, S. M. Reilly, A. J. Nunn, L. J. Teare, P. J. Fox, & A. J. Thompson (2005). Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *Journal of Neurology and Neurosurgical Psychiatry*, 76, 1664-1669.

Zarruk, Juan G., David Fernández-López, Isaac García-Yébenes, María S. García-Gutiérrez, José Vivancos, Florentino Nombela, Magdalena Torres, María C. Burguete, Jorge Manzanares, Ignacio Lizasoain, & María A. Moro (2011). Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternate brain macrophage/microglial activation concomitant to neuroprotection. *Stroke*, 43, 211-219.

Zuardi, A. W., J. A. S. Crippa, J. E. C. Hallak, F. A. Moreira, & F. S. Guimarães (2006). Cannabidiol, a *Cannabis sativa* constituent, as an antipsychotic drug. *Brazilian Journal of Medical and Biological Research*, 39, 421-429.

Chapter III: Gastrointestinal Health and Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the gastrointestinal system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the gastrointestinal system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the gastrointestinal system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for gastrointestinal disorders.

The Endocannabinoid System and THC and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder, acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, colon cancer has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of primary multifocal leukoencephalopathy (PML), which affects the neurological system, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the gastrointestinal system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert

antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of gastrointestinal disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects that are beneficial in the prevention and management of certain gastrointestinal disorders.

Human Gastrointestinal System

The human gastrointestinal system is responsible for the digestion of food and assimilation into the body. Beginning in the oral cavity, saliva facilitates the production of a bolus of matter, which is then swallowed, passing down the esophagus into the stomach. Amylase, which is contained in saliva, and gastric juices, breakdown food as peristalsis moves the matter to the small intestine. Chyme is dissolved in the small intestine and absorbed into the blood. Reabsorption of water and various minerals occurs in the colon of the large intestine and waste matter passes through the rectum to the anus for defecation.

The human gastrointestinal system is comprised of the upper and lower tracts. The upper gastrointestinal tract consists of the esophagus, stomach, and duodenum. The lower gastrointestinal tract consists of most of the small intestine and the large intestine. The accessory organs of the digestive system include the salivary glands, pancreas, liver, gallbladder, teeth, and tongue. These organs have a significant role in the digestive process, including mastication and taste (salivary), synthesis of bile salts, lipid and plasma protein metabolism, detoxification (liver), bile storage (gallbladder), and endocrine and exocrine functions (pancreas).

Gastrointestinal Health and Diseases

Diseases of the gastrointestinal system directly related to oxidative stress include disorders such as emesis, gastroesophageal reflux disease (GERD), gastric ulcer, irritable bowel syndrome, Crohn's Disease, colon cancer, and colorectal cancer. The human body evokes an active inflammatory response to mitigate damage from injury or infection via microglial cell and macrophage release. However, activation of microglial cells and macrophages is also associated with the release of glutamate, reactive oxidative species (ROS), nitric oxide (NO), and tumor necrosis factor (TNF), causing an escalation of inflammation, microvascular deterioration, and endocannabinoid degradation. Cannabidiol (CBD), according to El-Ramessay and Tang (2008), blocks the oxidative stress response and activation of proteins such as p-38 MAPK and microglial cells, reducing damage associated with inflammatory responses.

Nausea and Emesis

Endocannabinoid receptors, specifically CB1, located in the base of the fifth ventricle in the cerebral cortex, are associated with nausea and emesis. Emesis is associated with acquired clinical endocannabinoid deficiency (CECD), induced by infectious processes such as staphylococcus enteritis and chemotherapy, such as Adriamycin. Chronic and severe, acute emesis is associated with electrolyte imbalance and dehydration, which can be life-threatening. Research supports treatment with THC and cannabidiol (CBD) to increase circulating cannabinoids, which are decreased in antigen and pharmacological blockade.

Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux disease (GERD) is a chronic disorder caused by a failure of the lower esophageal sphincter, a valve which inhibits stomach acid, duodenal bile, and enzymes from returning to the esophagus. Failure of the esophageal sphincter causes chronic inflammation, pain, and mucosal damage in the esophagus. Clinical endocannabinoid deficiency (CECD) in GERD is defined as acquired or genetic and affects CB1 receptors in the gastrointestinal tract. Research indicates that administration of cannabidiol (CBD) increases circulating endocannabinoids, reducing esophageal sphincter pressure, and directly protects the gastric mucosa, rendering CBD useful in both prevention and management of GERD.

Gastric Ulcer

Gastric ulceration refers to a localized area of erosion of the stomach lining. Abdominal pain and bleeding are associated with gastric ulceration. Often, Heliobacter pylori, a type of bacteria found in contaminated food and water, is present upon endoscopy. Triple antibiotic therapy is instituted to address Helicobacter pylori. Clinical endocannabinoid deficiency (CECD) in gastric ulceration is classified as acquired, affecting the CB1 receptors in the gastrointestinal tract, which are associated with motility and gastric emptying, as well as CB2 receptors which modulate immune system response in the presence of infections. Research indicates that administration of cannabidiol (CBD) improves CB1 receptivity and increases cannabinoid availability, thereby improving reduced stasis associated with gastric erosion.

Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder, which affects the motility of the colon and associatively, the consistency of the fecal matter, without damaging the gastrointestinal mucosa. By definition, the symptoms of abdominal pain exceeding three times per month, relieved by a bowel movement, constitutes IBS. Subtyping of IBS into four categories: IBS with constipation (IBS-C), in which fecal matter is hard > 25% of the time with watery fecal matter > 25% of the time; IBS with diarrhea (IBS-D), with watery fecal matter 25% of the time and hard fecal matter greater than 25% of the time; Mixed IBS (IBS-M), with hard stools 25% of the time and watery stools 25% of the time, and Unsubtyped IBS (IBS-U), with hard stools and watery stools less than 25% of the time.

Clinical endocannabinoid deficiency (CECD) in IBS is considered idiopathic autoimmune and affects both cerebral and gastrointestinal CB1 and CB2 receptors. Glial cells actively mediate the inflammatory processes in the gastrointestinal system via CB2 receptors. Research has demonstrated that reactive inflammation in the bowel improved with the administration of Cannabidiol (CBD) with THC, which acts directly upon CB2 receptors in the bowel and CB1 receptors in the cerebral cortex, mediating the comorbidity factors of depression and anxiety which are integral in the manifestation of IBS.

Crohn's Disease
Crohn's disease, or regional enteritis, is an inflammatory bowel disease that can affect any part of the gastrointestinal tract and is associated with abdominal pain, diarrhea or occult positive stools, fever, and weight loss. Associated autoimmune symptoms external to the gastrointestinal tract include dermatitis, arthritis, fatigue, and ocular inflammation. Crohn's disease predisposes the individual to bowel obstruction and colon cancer. Clinical endocannabinoid deficiency (CECD) in Crohn's disease has both genetic and acquired classifications, since nicotine use increases the likelihood of developing this inflammatory bowel disease. Research indicates that cannabidiol (CBD) restores CB1 receptor capabilities, facilitating relaxation of the lower esophageal sphincter and modulation of colonic motility. Cannabidiol (CBD) administration also restores functionality of central and peripheral CB1 receptors, components of the endocannabinoid system that are imperative in the prevention and remediation of nausea and emesis.

Colon Cancer
Colon and colorectal cancers refer to the formation of malignancies in the tissues of the colon and rectum. Most of these malignancies are adenocarcinomas, which secrete mucus and other fluids. Clinical endocannabinoid deficiency (CECD) in colon and colorectal cancer is deemed genetic and acquired. CB1 and CB2 receptors in the gastrointestinal tract are targets for cannabidiol (CBD) and THC therapy because CBD with THC triggers cell death through an endoplasmic reticulum stress pathway, which activates autophagy and promotes apoptosis. Further, CBD upregulates the intracellular adhesion molecule, which decreases cancer cell invasiveness. Indeed, the use of cannabidiol (CBD) with THC is suggested to prevent colon and colorectal cancer through preservation of the endocannabinoid system and receptor functionality.

Pancreatic Cancer
The development of malignancy in the pancreas, a glandular organ based behind the stomach, occurs primarily in the third decade of life. Pancreatic adenocarcinoma represents the majority of the cases and the malignancy is generally diagnosed in an advanced stage, rendering a poor prognosis. Symptoms include darkened urine, poor appetite, weight loss, lightened feces, abdominal and back pain, and jaundice. Clinical endocannabinoid deficiency (CECD) in pancreatic cancer is classified as genetic and acquired, with over twenty-five percent of cases being associated with nicotine use, obesity, and diabetes.

Cannabidiol (CBD) has been demonstrated to inhibit pancreatic cancer cell growth through the stimulation of CB1 receptors in the pancreas. Cannabinoids inhibit reactive oxidative stress (ROS) and inhibits the Krebs cycle, culminating in an anti-tumoral effect. Mediation of cancer cell metabolism by cannabidiol (CBD) induces autophagy, the catabolic mechanism that involves the destruction of dysfunctional cellular components by liposomes, and malignant cell growth. Administration of cannabidiol (CBD) preventively in individuals at hereditary or acquired risk of pancreatic cancer is therefore warranted.

Hepatic Cancer
The liver filters the circulating blood continuously in the human body, converting substances absorbed from the gastrointestinal system into usable chemicals for absorption, and removing toxins and chemical byproducts, which are then excreted. The likelihood of hepatocellular carcinoma increases because of the function of the liver. Predisposition to hepatic cancer arises directly from hepatitis, and secondarily from metastasis from a primary malignant site, such as the lung. Clinical endocannabinoid deficiency (CECD) in hepatocellular carcinoma is classified as acquired, and associated with infectious hepatitis B and C, and alcohol and nicotine use. Symptoms included jaundice, weight loss, nausea and emesis, and abdominal pain. Research noted anti-tumoral effect in hepatocellular carcinoma attributable to induction of cancer cell death, inhibition of cell proliferation, and inhibition of tumor angiogenesis. In hepatic malignancy, cannabinoids appear to kill tumor cells and protect non-transformed cells from malignancy, supporting use of cannabidiol (CBD) preventively in individuals at risk of developing hepatocellular carcinoma and among individuals diagnosed with metastasis to the liver from a primary source.

Cirrhosis
Cirrhosis of the liver refers to the development of fibrosis scarring of the liver and the formation of regenerative nodules, which appear as the organ attempts to repair the damage. Cirrhosis is most often associated with alcoholism, hepatitis B, hepatitis C, and fatty liver disease. Ascites and hepatic encephalopathy, portal hypertension and esophageal varices are life-threatening complications of cirrhosis. Liver transplantation has been poised as the only option in advanced cirrhosis.

Clinical endocannabinoid deficiency (CECD) is acquired in cirrhosis of the liver, attributable to the aforementioned risk factors. Research has shown that stimulation of CB2 receptors with cannabidiol (CBD) reduced portal hypertension, infiltration of inflammatory cells, and decreased fibrosis. In the management of cirrhosis of the liver, cannabidiol (CBD) is suggested for individuals in the early stages of cirrhosis and those at greatest risk for the development of the disease.

Endocannabinoid Deficiency (CECD) Classification: Gastrointestinal Disorders

Disorder	Origin of CECD
GERD	Acquired
Gastric ulcer	Acquired
IBS	Genetic
Crohn's disease	Genetic
Colon and Colorectal Cancer	Genetic
Pancreatic Cancer	Acquired
Cirrhosis of liver	Acquired

CEN Medical Cannabis Pharmacological Prescription and Coding System:
Gastrointestinal Disorder Application
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: Cannabidiol (CBD oil) is recommended for the patient. The concentration of the CBD oil is 19.5% and the patient is to ingest 50 mg. of CBD oil four times each day every six hours, as adjunctive therapy in the treatment of colon cancer, (ICD-9: 363.20). The prescription would therefore read:

Charles Gary Reynolds
Date of Birth: 09-01-1939.
Diagnosis: Adenocarcinoma of the colon, ICD-9 code: 153.9
CBD: 0.00%/ 19.5%. Take 50 mg. of CBD oil by mouth four times daily, every 6 hours. Use dropper as indicated.
Zakra Kahn, M.D.

The patient would then be able to purchase the CBD oil online or at a dispensary, offering the prescription to the pharmacist or technician.

THC is also recommended for discomfort. The patient would be able to purchase this at a dispensary.

Charles Gary Reynolds
Date of Birth: 09-01-1939
Diagnosis: Adenocarcinoma of the colon, ICD-9: 153.9
CS: 15-20%/ 1.1%
Use every four hours via vaporizer as needed.
Zakra Kahn, M.D.

Composition Assignments
1. Please answer the following question. Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with abdominal pain secondary to liver disease.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the gastrointestinal system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Alhamouruni, A., K. I. Wright, M. Larvin, & S. E. O'Sullivan (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. *British Journal of Pharmacology*, 165, 2598-2610.

Alhouayek, Mireille & Giulio G. Muccioli (2012). The endocannabinoid system in inflammatory bowel disease: from pathophysiology to therapeutic opportunity. *Trends in Molecular Medicine*, 18(10), 615-626.

Avraham, Y., N. C. Grigoradis, T. Poutahidis. L. Vorobiev, I. Magen, Y. Ilan, R. Mechoulam, & E. M. Berry (2011). Cannabidiol improves brain function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. *British Journal of Pharmacology*, 162, 1650-1658.

Baldassare, M., M. Domenicali, F. A. Giannone, M. Laggetta, F. Fanelli, M. Mezzullo, U. Pagotto, M. Ber\nardi, & P. Caraceni (2014). Endocannabinoids and liver disease: the endocannabinoid-related molecule oleoyl-ethanolamine (OEA) correlates with clinical complications and 1-year survival. *Digestive Disease and Liver Disease*, 46, 33.

Barakat, Eman Mahmoud Fathy, Lamia Mohamed El Wakeel, & Radwa Samir Hagag (2013). Effects of *Nigella sativa* on outcome of hepatitis C in Egypt. *World Journal of Gastroenterology*, 19(16), 2529-2536.

Basu, P. P., M. M. Aloysius, N. J. Shah, & R. S. Brown, Jr (2014). Review article: endocannabinoid system in liver disease, a potential therapeutic target. *Alimentary Pharmacology and Therapeutics*, 39, 790-801.

Bátkai, Sándor, Partha Mukhopadhyay, Judith Harvey-White, Raouf Kechrid, Pál Pacher, & George Kunos (2007). Endocannabinoids acting as CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. *American Journal of Physiology-Heart and Circulatory Physiology*, 293(3), 1689-1695.

Bátkai, Sándor, Douglas Osei-Hyiaman, Hao Pan, Osama El-Assal, Mohanraj Rajesh, Partha Mukhopadhyay, Feng Hong, Judith Harvey-White, Anjum Jafri, György Haskó, John W. Huffman, Bin Gao, George Kunos, & Pál Oacher (2007). Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. *Federation for American Societies for Experimental Biology*, 21(8), 1788-1800.

Borelli, Francesca, Gabriella Aviello, Barbara Romano, Pierangelo Orlando, Raffaele Capasso, Francesco Maiello, Federico Guadagno, Stefania Petrosino, Francesco Capasso, Vincenzo di Marzo, & Angelo A. Izzo (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant *Cannabis sativa*, is protective in a murine model of colitis. *Journal of Molecular Medicine*, 87, 1111-1121.

Brunet, Laurence, Erica M. Moodie, Kathleen Rollet, Curtis Cooper, Sharon Walmsley, Martin Potter, & Marina B. Klein (2013). Marijuana smoking does not accelerate progression of liver disease in HIV-Hepatitis coinfection: a longitudinal cohort analysis. *Canadian Journal of Infectious Diseases*, 57, 663-670.

Cao, Ming-hua, Yong-yu Li, Jing Xu, Ya-jing Feng, Xu-hong Lin, Kun Li, Tong Han, & Chang-jie Chen (2012). Cannabinoid HU210 protects isolated rat stomach against impairment caused by serum of rats with experimental acute pancreatitis. *PLOS One*, 7(9), 1-9.

Capasso, R., F. Borrelli, G. Aviello, B. Romano, C. Scalisi, F. Capasso, & A. A. Izzo (2008). Cannabidiol, extracted from *Cannabis sativa*, selectively inhibits inflammatory hypermobility in mice. *British Journal of Pharmacology*, 154, 1001-1008.

Caraceni, P. M. Domenicali, A. Viola, F. Picitelli, S. Petrosino, F. Giannone, A. Berzigotti, M. Zoli, V. di Marzo, & M. Bernardi (2009). Endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis. *Digestive and Liver Disease*, A14.

Chen, Si-Wen, Ben-Yan Wu, Shi-Ping Xu, Ke-Xing Fan, Li Yan, Yuan Gong, Jun-Bao Wen, & Dao-Hong Wu (2012). Suppression of CB1 cannabinoid receptors by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats. *PLOS One*, 7(12), 1-9.

Cianchi, Fabio, Laura Papucci, Nicola Schiavone, Matteo Lulli, Lucia Messerini, Maria Cristina Vinci, Luca Messerini, Clementina Manera, Elisa Ronconi, Paolo Romagnani, Martino Donnini, Giuliano Perigli, Giacomo Trallori, Elisabetta Tanganelli, Sergio Capaccioli, & Emanuela Masini (2008). Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide *de novo* synthesis in colon cancer cells. *Clinical Cancer Research*, 14(23), 7691-7700.

Coutts, Angela A. & Angelo A. Izzo (2004). The gastrointestinal pharmacology of cannabinoids: an update. *Current Opinion in Pharmacology*, 4, 572-579.

Dando, I., M. Donadelli, C. Constanzo, E. Dalla Pozza, A. D'Alessando, L. Zolla, & M. Palmer (2013). Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Cell Death and Disease*, 1-10.

De Filippis, Daniela, Giuseppe Esposito, Carlo Cirillo, Mariateresa Cipriano, Benedict Y. de Winter, Caterina Scuderi, Giovanni Sarnelli, Rosario Cuomo, Luca Steardo, Joris G. de Man, & Teresa Iuvone (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. *PLOS One*, 6(12), 1-8.

De Filippis, D., T. Iuvone, A. D'Amico, G. Esposito, L. Steardo, A. G. Herman, P. A. Pelckmans, B. Y. de Winters, & J. G. Man (2008). Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB1 receptors and fatty acid hydrolase. *Neurogastroenterology and Motility*, 20, 919-927.

De Petrocellis, L., P. Orlando, A. Sciano Moriello, G. Aviello, C. Stott, A. A. Izzo, & V. di Marzo (2012). Cannabinoid actions at TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. *Acta Physiologica*, 204, 255-266.

Di Marzo, V., R. Capasso, I. Matias, G. Aviello, S. Petrosino, B. Romano, P. Orlando, F. Capasso, & A. A. Izzo (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high fat diet. *British Journal of Pharmacology*, 153, 1271-1280.

Di Sabatino, A., N. Battista, P. Biancheri, P. Cazzola, A. Vanoli, C. Alvisi, M. Perego, G. Astarita, D. Piomelli, M. Maccarrone, & G. R. Corazza (2008). A key role for the endocannabinoid system in inflammatory bowel disease. *Digestive and Liver Disease*, S7.

Donadelli, M., I. Dando, T. Zaniboni, C. Costanzo, E. Dalla Pozza, M. T. Scupoli, A. Scarpa, S. Zappavigna, M. Marra, A. Abbruzzese, M. Bifulco, M. Caraglia, & M. Palmieri (2012). Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. *Cell Death and Disease*, 1-12.

Fathy, Moustafa & Toshio Nikaido (2013). In vivo modulation of iNOS pathway in hepatocellular carcinoma by *Nigella sativa*. *Environmental Health and Preventive Medicine*, 18, 377-385.

Fichna, Jakub & Martin A. Storr (2012). Brain-gut interactions in IBS. *Frontiers in Pharmacology*, 2, 1-12.

Fichna, Jakub, JodiAnne T. Wood, Malvina Papanastasiou, Subramanian K. Vadivel, Piotr Oprocha, Maciej Salaga, Marta Sobczak, Anna Mokrowiecka, Adam I. Cyangkiewicz, Piotr k. Zakrzewski, Ewa Malecka-Panas, Wanda M. Krajewski, Piotr Koscielniak, Alexandros Makriyannis, & Martin A. Storr (2013). Endocannabinoids and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. *PLOS One*, 8(12), 1-9/

Frampton, Gabriel, Monique Coufal, Huang Li, Jonathan Ramirez, & Sharon DeMorrow (2010). Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. *Experimental Cell Research*, 316(9), 1465-1478.

Garella, R. & M. C. Baccari (2012). Endocannabinoids modulate non-adrenergic, non-cholinergic inhibitory neurotransmission in strips from the mouse gastric fundus. *Acta Physiologica*, 206, 80-87.

Gerick, Mark E., Robert W. Isfort, Bryan Brimhall, & Corey A. Siegel (2014). Medical marijuana for digestive disorders: high time to prescribe? *American Journal of Gastroenterology*, 1-7.

Hedge, Venkatesh L., Shweta Hedge, Benjamin F. Cravatt, Lorne J. Hofseth, Mitzi Nagarkatti, & Prakash S. Nagarkatti (2008). Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids involvement of regulatory T cells. *Molecular Pharmacology*, 74(1), 20-33.

Hölzer, Peter (2011). Transient receptor potential (TRP) channels as drug targets for disease of the digestive system. *Pharmacology & Therapeutics*, 131, 142-170.

Huang, Li, Matthew A. Quinn, Gabriel A. Frampton, L. Eric Golden, & Sharon DeMorrow (2011). Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. *Digestive and Liver Disease*, 43(3), 188-193.

Izzo, Angelo A. (2004). Cannabinoids and intestinal motility: welcome to CB2 receptors. *British Journal of Pharmacology*, 142, 1201-1202.

Izzo, Angelo A., Gabriella Aviello, Stefania Petrosino, Pierangelo Orlando, Giovanni Marsciano, Beat Lutz, Francesca Borrelli, Raffaele Capasso, Santosh Nigam, Francesco Capasso, & Vincenzo di Marzo (2008). Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. *Journal of Molecular Medicine*, 86, 89-98.

Izzo, Angelo A., Nicola Mascolo, & Francesco Capasso (2001). The gastrointestinal pharmacology of cannabinoids. *Current Opinion in Pharmacology*, 1, 597-603.

Jourdan, Tony, Grzegorz Godlewski, Resat Cinar, Adeline Bertola, Gergö Szanda, Jie Liu, Joseph Tarn, Tiffany Han, Bani Mukhopadhyay, Monica C. Skarulis, Cynthia Ju, Myriam Aouadis, Michael P. Czech, & George Kunos (2013). Activation of the Nirp3 inflammasome in infiltrating macrophages by endocannabinoid mediates beta cell loss in type 2 diabetes. *Nature Medicine*, 19(9), 1132-1140.

Li Chen, Peter M. Jones, & Shanta Persaud (2011). Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. *Pharmacology & Therapeutics*, 129, 307-320.

Lin, X. H., B. Yuece, Y. Y. Li, Y. J. Feng, L. Y. Yu, K. Li, Y. N. Li, & M. Storr (2011). A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. *Neurogastroenterology and Motility*, 23, 862-342.

Liu, Jie, Liang Zhou, Keming Xiong, Grzegorz Godlewski, Bani Mukhopadhyay, Joseph Tam, Shi Yin, Peter Gao, Xin Shan, James Pickel, Ramon Bataller, James O'Hare, Thomas Scherer, Cristoph Buettner, & George Kunos (2012). Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. *Gastroenterology*, 142(5), 1218-1228.

Magen, I., Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam, & E. M. Berry (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT (1a) receptor activation. *British Journal of Pharmacology*, 159, 950-957.

Maggioli, C., F. A. Giannone, M. Baldassare, F. Fanelli, M. Messullo, I. Bellumom, M. Domencali, P. Caraceni, & M. Bernardi (2012). Endocannabinoids in advanced cirrhosis: have we picked the right one? *AISF*, 44, 40.

Malfitano, Anna Maria, Elena Ciaglia, Giuseppina Gangemi, Patrizia Gazzerro, Chiara Laezza, Update on the endocannabinoid system as an anticancer target. *Expert Opinion on Therapeutic Targets*, 15(3), 297-308.

Mallat, Ariane, Fatima Teixeira-Clerc, & Sophie Lotersztajn (2013). Cannabinoid signaling and liver therapeutics. *Journal of Hepatology*, 59, 891-896.

Mallat, A., F. Teixeira-Clerc, V. Deveraux, S, Manin, & S. Lotersztajn (2011). The endocannabinoid system as a key mediator during liver disease: new insights and therapeutic openings. *British Journal of Pharmacology*, 163, 1432-1440.

Manera, L. T. Croci, F. Guagnini, M. Rinaldi-Carmona, J.-P Maffrand, G. LeFur, S. Mulenge, & G. Ferla (2002). Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. *Digestive and Liver Disease*, 34, 262-269.

Marquez, Lucia, Juan Suarez, Mar Iglesias, Francisco Javier Bermudez-Silva, Fernando Rodriguez de Fonseca, & Montserrat Andreu (2009). Ulcerative colitis induces changes on the endocannabinoid system in the human colonic tissue. *PLOS One*, 4(9), 1-13.

Michalski, Christoph W. Florian E. Oti, Mert Erkan, Danguole Sauliunaite, Frank Bergmann, Pal Pacher, Sandor Batkai, Michael W. Müller, Nathalia A. Giese, Helmüt Friess, & Jorg Kleeff (2008). Cannabinoids in pancreatic cancer: correlation with survival and pain. *International Journal of Cancer*, 122(4), 742-750.

Pacher Pal & Bin Gao (2008). Endocannabinoids and Liver Disease. III. Endocannabinoids effects on immune cells: implications for inflammat.ory liver disease. *American Journal of Gastrointestinal-Liver Physiology*, 294(4), 850-854

Pandey, Rupal, Venkatesh L. Hedge, Narenda P. Singh, Lorne Hofseth, Uday Singh, Swapan Ray, Mitzi Nagarkatti, & Prakash Nagarkatti (2009). Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. *Vitamins and Hormones*, 81, 487-504.

Pandurangan, Ashok Kumar (2013). Poyential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. *Asian Pacific Journal of Cancer Prevention*, 14(4), 2201-2205.

Park, Jae Myung, Xiang-Shu Xian, Myung –Gyu Choi, Hyeyeon Park, Yu Kyung Cho, In Seok Lee, Sang Woo Kim, & In-Sik Chung (2011). Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. *Journal of Cellular Biochemistry*, 112, 1192-1205.

Patsos, H. A., D. J. Hicks, R. H. Dobson, A. Greenhough, N. Woodman, J. D. Lane, A. C. Williams, & C. Paraskeva (2005). The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. *Gut*, 54, 1741-1750.

Patsos, H. A., D. J. Hicks, A. Greenhough, A.C. Williams, & C. Paraskeva (2005). Cannabinoids and cancer: potential for colorectal cancer therapy. *Biochemical Society Transactions*, 13(4), 712-714.

Petrosino, Stefania, Alessia Ligresti, & Vincenzo di Marzo (2009). Endocannabinoid chemical biology: a tool for the development of novel therapies. *Current Opinion in chemical Biology*, 13, 309-320.

Prestifilippo, J. P., V. A. Medina, C. E. Mohn, P. A. Rodriguez, J. C. Elverdin, & J. Fernandez-Solari (2013). Endocannabinoids mediate hyposalivation induced by inflammogens in the submandibular glands and hypothalamus. *Archives of Oral Biology*, 58, 1251-1259.

Romano, B. F. Borrelli, I. Fasolino, R. Capasso, F. Piscitelli, M. G. Cascio, R. G. Pertwee, D. Coppola, L. Vassallo, P. Orlando, V. di Marzo, & A. A. Izzo (2013). The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. *British Journal of Pharmacology*, 169, 213-229.

Ruby, Maxwell A., Daniel K. Nomura, Carolyn S. S. Hudak, Anne Barber, John E. Casida, & Ronald M. Krauss (2011). Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genes. *PLOS One*, 6(11), 1-9.

Salaga, M., A. Mokrowiecka, P. K. Zakrzewski, A. Cygankiewicz, E. Leishman, M. Sobczak, H. Zatorski, E. Malecka-Panas, R. Kordek, M. Storr, W. M. Krajewska, & B. Bradshaw (2014). Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). *Journal of Crohn's and Colitis*, 8, 998-1009.

Schicho, Rudolf, Mohammad Bashashati, Misha Bawa, Douglas McHugh, Dieter Saur, Huang-Ming Hu, Andreas Zimmer, Beat Lutz, Ken Mackie, Heather B, Bradshaw, Donna-Marie McCafferty, Keith A. Sharkey, & Martin Storr (2011). The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. *Inflammatory Bowel Disease*, 17(8), 1651-1664.

Schicho, Rudolf & Martin Storr (2011). Alternative targets within the endocannabinoid System for future treatment of gastrointestinal diseases. *Canadian Journal of Gastroenterology*, 25(7), 377-383.

Schicho, Rudolf & Martin Storr (2012). Topical and systemic cannabidiol improves trinito-benzene sulfonic acid colitis in mice. *Pharmacology*, 89, 149-155.

Scopinho, América A., Francisco S. Guimãraes, Fernando M. A. Correa, & Leonardo B. M. Resstel (2011). Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists. *Pharmacology, Biochemistry and Behavior*, 98, 268-272.

Silvestri, Cristoforo & Vincenzo di Marzo (2013). The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. *Cell Metabolism*, 17, 475-491.

Singh, Udai P., Narenda P. Singh, Balwan Singh, Robert L. Price, Mitzi Nagarkitti, & Prakash S. Nagarkatti (2012). Cannabinoids receptor-2 (CB2) agonist ameliuorates colitis in IL-10 mice by attenuating the activation of T cells and promoting their apoptosis. *Toxicology of Applied Pharmacology*, 258(2), 256-267.

Sreevalsan, Sandeep, Sonia Joseph, Indira Jutooru, Gayathri Chadalapaka, & Stephen H. Safe (2011). Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. *Anticancer Research*, 31(11), 3799-3807.

Sreevalsan, Sandeep & Stephen Sale (2013). The cannabinoid WIN 55, 212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells. *Molecular Cancer Therapeutics*, 12, 2483-2493.

Storr, Martin A. & Keith A. Sharkey (2007). The endocannabinoid system and gut-brain signaling. *Current Opinion in Pharmacology*, 7, 575-582.

Tam, Joseph, Resat Cinar, Jie Liu, Grzegorz Godlewski, Daniel Wesley, Tony Jourdan, Gergo Szanda, Bani Mukhopadhyay, Lee Chedester, Jeih-San Liow, Robert B. Innis, Kejun Cheng, Kenner C. Rice, Jeffrey R. Deschamps, Robert J. Chorvat, John F. McElroy, & George Kunos (2012). Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. *Cell Metabolism*, 16, 167-179.

Tam, Joseph, Jie Liu, Bani Mukhopadhyay, Resat Cinar, Grzegorz Godlewski, & George Kunos (2011). Endocannabinoids in liver disease. *Hepatology*, 53, 346-355.

Vasquez-Roque, Maria I., Michael Camilleri, Adrian Vella, Paula Carlson, Jeanette Laugen, and Alan R. Zinmeister (2011). Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity. Neurogastroenterology and Motility, 23, 7, 637-e257.

Wong, Banny S., Michael Camilleri, Irene Busciglio, Paula Carlson, Lawrence S. Szarka, Duane Burton, & Alan R. Zinsmeister (2011). Pharmacogenic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with non-constipated irritable bowel syndrome. *Gastroenterology*, 141(5), 1638-1647.

Wright, Karen, Nicholas Rooney, Mark Feeney, Jeremy Tate, Duncan Robertson, Melanie Welham, & Stephen Ward (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. *Gastroenterology*, 129, 437-453.

Xian, Xiang-Shu, Hyeyeon Park, Yu Kyung Cho, In Seok Lee, Sang Woo Kim, Myung-Gyu Choi, In-Sik Chung, Ki-Hwan Han, & Jae Myung Park (2010). Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. *Journal of Cellular Biochemistry*, 10, 321-332.

Ziv, Ehud, Lola Weiss, Itamar Raz, Natan Patlas, Zhanna Yekhtin, & Ruth Gallily (2014). Islet protection and amelioration of diabetes type 2 in *Psammomys obesus* by treatment with cannabidiol. *Journal of Diabetes Mellitus*, 2(1), 27-34.

Chapter IV: Musculoskeletal Health and Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the musculoskeletal system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the musculoskeletal system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the musculoskeletal system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for musculoskeletal disorders.

The Endocannabinoid System and THC and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems, as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, diabetes has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of rheumatoid arthritis, which affects the musculoskeletal and immune systems, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the musculoskeletal system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has neuroprotective and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert

antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of musculoskeletal disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects that are beneficial in the prevention and management of certain musculoskeletal disorders.

Human Musculoskeletal System
The human musculoskeletal system is a complex organ system, which provides the structure and support for the function of movement. Comprised of skeleton, muscle, cartilage, tendons, ligaments, joints, and connective tissue, the musculoskeletal system supports and protects the internal organs, and provides form to the human body. Calcium and phosphorus are stored in the human skeleton and hematopoietic components arise from the bone marrow. Muscle fibers and connective tissues adhere to the skeletal system, providing form, and bones are bound to each through joints, with cartilage protecting the ends of bone as they interact with one another. The contraction of muscles enables movement of the bone attached to a respective joint.

The endocannabinoid system affects the function and integrity of the musculoskeletal system. CB1 and CB2 receptors are located throughout the musculoskeletal system and are targets for the treatment of disorders of movement, and diseases of bone and muscle that are related to clinical endocannabinoid deficiencies (CECD).

Musculoskeletal Health and Diseases
Diseases of the musculoskeletal system directly related to clinical endocannabinoid deficiency (CECD) and associated reactive oxidative stress, include disorders such as osteoarthritis, rheumatoid arthritis, osteoporosis, bone cancer, bone fracture, and muscle spasm. The human body evokes an active inflammatory response to mitigate damage from injury or malignancy via microglial cell and macrophage release. However, activation of microglial cells and macrophages is also associated with the release of glutamate, reactive oxidative species (ROS), nitric oxide (NO), and tumor necrosis factor (TNF), causing an escalation of inflammation, microvascular and osteoblast and osteoclast deterioration, and endocannabinoid degradation. Cannabidiol (CBD), according to El-Ramessay and Tang (2008), blocks the oxidative stress response and activation of proteins such as p-38 MAPK and microglial cells, reducing damage associated with inflammatory responses.

Osteoarthritis
The most common form of arthritis, osteoarthritis, causes an inflammatory response, which affects the musculoskeletal system, including joint, bone, and cartilage. Symptoms include pain, limited range of motion, and swelling of the affected area. As osteoarthritis degrades cartilage

over time, direct contact between bones increases symptoms. A disorder of the skeletal system, which affects joints and cartilage as well and bone, osteoarthritis most commonly occurs in the spine, knees, hips, and hands.

Clinical endocannabinoid deficiency (CECD) associated with osteoarthritis is both genetic and acquired, affecting CB2 receptors in the musculoskeletal system. Risk factors associated with acquired CECD related to osteoarthritis include obesity, sedentary lifestyle, smoking, and traumatic injury. Administration of cannabidiol (CBD) with THC preventatively and post-diagnosis of osteoarthritis is suggested to reduce the inflammatory response throughout the musculoskeletal system, and increase anandamide production, which enhances cannabinoid binding to CB2 receptors, thereby reducing cartilage destruction.

Rheumatoid Arthritis
Rheumatoid arthritis is a multisystemic idiopathic autoimmune disorder, which affects the musculoskeletal system and manifests as a progressive deterioration of the joints, primarily. As a secondary manifestation, rheumatoid arthritis affects the cardiac, pulmonary, and ocular systems. Pain and debilitation reduce mobility and function over time. CB2 receptors are affected in the idiopathic autoimmune clinical endocannabinoid deficiency (CECD) associated with rheumatoid arthritis, causing an abnormal inflammatory response. Research indicates that prophylactic administration of cannabidiol (CBD) with THC reduces inflammatory responses by enhancing receptivity to binding via lipid neurotransmitters bolstered by CBD administration. CBD with THC is recommended after diagnosis as well, as adjunctive therapy with medications and physical therapy to manage symptoms and enhance mobility in rheumatoid arthritis.

Bone Cancer
Malignancy of the bone can be either primary or secondary. Bone-derived malignancies arise from cells and tissues of the skeletal system. Secondary bone cancers metastasize from primary cancer sites, including carcinomas of the prostate, breast, thyroid, lungs, and kidneys. Clinical endocannabinoid deficiency (CECD) associated with bone cancers are idiopathic autoimmune and reflect abnormality in CB2 receptor function. Research supports using cannabidiol (CBD) with THC to prevent metastasis from primary cancer sites, as well as prophylactic use in adult populations.

Osteoclast Formation
Osteoclast formation involves the re-absorption of bone tissue, which is critical for the maintenance, repair, and restructuring of the skeletal system. The osteoclast disassembles and reabsorbs bone and osteoblasts form new bone. The endocannabinoid system controls the immune function via the CB2 receptors in the skeletal system, regulating cellular production. Clinical endocannabinoid deficiency (CECD) associated with osteoclast impairment is defined as idiopathic autoimmune. Reduction in osteoclast formation affects the stability and strength of the skeletal system. Research indicates that increasing levels of lipid neurotransmitters, such as anandamide, using cannabidiol (CBD) increases production of viable osteoclasts, thereby reducing and/or ceasing osteoclast deterioration and associated skeletal manifestations.

Osteoporosis
Osteoporosis is a disorder of the skeletal system, which causes progressive reduction in bone mass and density, altering the proteins within the bones. As microstructural changes occur in osteoporosis, the likelihood of fracture and pain occurs with alterations in posture. Considered genetic and acquired relative to clinical endocannabinoid deficiency (CECD), osteoporosis affects primarily perimenopausal women and the elderly and is associated with morbidity and mortality related to hip and spinal fractures. Administration of cannabidiol (CBD) is highly recommended for at-risk populations, because CB2 receptors are critical in the regulation of bone cell homeostasis.

Bone fracture
Traumatic injury to the bone is associated with pain, reduced mobility, and reduced range of motion. The endocannabinoid system regulates osteoblast and osteoclast formation via CB2 receptors. In acquired CECD, administration of cannabidiol (CBD) reduces abnormal inflammatory responses, increases the production of viable osteoblast and osteoclasts, and provides analgesic benefit. Cannabidiol (CBD) is recommended for adults throughout the lifespan to reduce the severity of bone fracture in the event of trauma, and enhance the recovery in the event of a traumatic injury.

Muscle Spasm
The contraction of involuntary muscles, which produce a hypertonic response and associated pain, defines spasm. The incident and force of muscle spasm is associated with the excitatory CB1 receptor, a component of the endocannabinoid system. In clinical endocannabinoid deficiency (CECD), which affects the musculoskeletal system, anandamide levels decrease, causing hyperactivity of misdirected nerve impulses. An acquired CECD, spasm of the muscle, causes debilitating pain and immobility. Restoration of the CB1 receptor uptake via cannabidiol (CBD) with THC administration produces analgesia. Similarly, increased CB2 function reduces abnormal immunological responses, thereby reducing inflammation around the affected area. Cannabidiol (CBD) is recommended preventatively for athletes and active adults to prevent sudden onset of muscle spasms and post-incident with analgesics and physical therapy to reduce symptoms.

Sarcoma of the Muscle
Malignancy of the muscle, defined as sarcoma of the muscle, is associated with tumor production. Clinical endocannabinoid deficiency (CECD), considered idiopathic in sarcoma of the muscle, can be restored with cannabidiol (CBD) with THC and used as adjunctive treatment with chemotherapy and genetic augmentation to treat sarcoma of the muscle. Because metastasis is common with this malignancy, early intervention with cannabidiol (CBD) with THC is warranted to reduce the incidence of malignant cell proliferation.

Endocannabinoid Deficiency (CECD) Classification: Neurological Disorders

Disorder	Origin of CECD
Osteoarthritis	Idiopathic Autoimmune, Acquired
Rheumatoid Arthritis	Idiopathic Autoimmune
Bone Cancer	Idiopathic Autoimmune
Bone Fracture	Acquired
Muscle Spasm	Acquired
Osteoclast Formation	Idiopathic Autoimmune
Osteoporosis	Genetic, Acquired
Sarcoma of the Muscle	Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System:
Musculoskeletal Disorder Application

The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: The patient presents with severe lumbar pain. The prescription for cannabis sativa would therefore read:

Jane Smith
DOB: 11-09-1950
Lumbar stenosis, ICD-9 724.02
CS: 18-20%/ 4-6%
Use via vaporizer every four hours as needed for pain.
Margaret Holder, M.D.

The patient would then be able to purchase the CBD oil online and the cannabis sativa at a dispensary, offering the prescription to the pharmacist or technician.

Composition Assignments:
1. Please answer the following question. Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with osteopenia.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the musculoskeletal system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Bab, I. & A. Zimmer (2008). Cannabinoid receptors and the regulation of bone mass. *British Journal of Pharmacology*, 153, 182-188.

Biró, Tamás, Balaázs I. Tóth, György Haskó, Ralf Paus, & Pál Pacher (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. *Trends in Pharmacological Sciences*, 30(8), 411-420.

Coutts, Angela A. & Roger G. Pertwee (1997). Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. *British Journal of Pharmacology*, 121, 1557-1566.

Elefteriou, Florent (2008). Regulation of bone remodeling by the central and peripheral nervous system. *Archives of Biochemistry and Biophysics*, 473(2), 231-236.

Fitzcharles, Mary-Ann, Jason McDougall, Peter A. Ste-Marie, & Ivan Radjen (2012). Clinical applications for cannabinoid use in the rheumatic diseases. *Arthritis & Rheumatism*, 64(8), 2417-2425.

Fleming, I., B. Schermer, R. Popp, & R. Busse (1999). Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. *British Journal of Pharmacology*, 126, 949-960.

Gowran, Aoife, Katey McKayed, & Veronica A. Campbell (2013). The cannabinoid receptor type 1 is essential for mesenchymal stell cell survival and differentiation: implications for bone health. *Stem Cells International*, 1-8.

Gowran, Aoife, Katey McKayed, Manoj Kanichai, Cillian White, Nissrin Hammadi, & Veronica Campbell (2010). Tissue engineering of cartilage: can cannabinoids help? *Pharmaceuticals*, 3, 2970-2985.

Idris, Aymen I. (2010). Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. *Current Neuropharmacology*, 8, 243-253.

Idris, Aymen I. (2012). The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. *International Bone & Mineral Society*, 224, 1-7.

Idris, Aymen I & Stuart H. Ralston (2012). Role of endocannabinoids in the regulation of bone remodeling. Frontiers in Endocrinology, 3(136), 1-8.

Idris, Aymen I., Robert J. van't Hof, Iain R. Greig, Susan A. Ridge, David Baker, Ruth A. Ruth A. Ross (2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. *Nature Medicine*, 11(7), 774-779.

Khasabova, Iryna A., Anisha Chandiramani, Catherine Harding-Rose, Donald A. Simone, & Virginia S. Seybold (2011). Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. *Pharmacological Research*, 64(1), 60-67.

Khasabova, I. A., S. G. Khasabov, C. Harding-Rose, L. G. Coicou, B. A. Seybold, A. E. Lindberg, C. D. Steevens, D. A. Simone, & V. S. Seybold (2008). A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. *Journal of Neuroscience*, 28(44), 11141-11152.

La Porta, Carmen, Simona Andreea Bura, Auxiliadora Aracil-Fernandez, Jorge Mansanares, & Rafael Maldonado (2013). Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. *PAIN*, 154, 160-174.

Malfait, A. M., R. Gallily, P. F. Sumarlwalla, A. S. Malik, E, ANdreakos, R. Mechoulam, & M. Feldmann (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collage-induced arthritis. *Proceeding of the National Academy of Sciences*, 97(17), 9561-9566.

Martins, D. F., L. Mazzardo-Martins, F. J. Cidral-Filho, V. M. Gadotti, & A. R. S. Santos (2013). Peripheral and spinal activation of cannabinoid receptors by joint mobilization alleviates postoperative pain in mice. *Neuroscience*, 255, 110-121.

McPartland, John M. (2008). Expression of the endocannabinoid system in fibroblasts and myofascial tissues. *Journal of Bodywork and Movement Therapies*, 12, 169-182.

Olah, Attila, Balazs I. Toth, Istvan Borbiro, Koji Sugawara, Attila G. Szollosi, Gabriella Czifra, Balazs Pal, Lidia Ambrus, Jennifer Kloepper, Emanuela Camera, Matteo Ludovici, Mauro Picardo, Thomas Voets, Christos C. Zouboulis, Ralf Paus, & Tamas Biro (2014). Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes. *The Journal of Clinical Investigation*, 124(9), 3713-3724.

Pertwee, Roger G. (2005). The therapeutic potential of drugs that target cannabinoid receptors that modulate the tissue levels or actions of endocannabinoids. *The American Association of Pharmaceutical Scientists*, 7(3), E625-E654.

Petrovszki, Zita, Gyula Kovacs, Csaba Tömböly, György Benedek, & Gyongyi Horvath (2012). The effects of peptide and lipid endocannabinoids on arthritic pain at the spinal level. Anaesthesia, 114(6), 1146-1152.

Rajesh, Mohanraj, Partha Mukhopadhyay, Sandor Batkai, Gyorgy Hasko, Lucas Liaudet, Viktor R. Drel, Irina G. Obrosova, & Pal Pacher (2007). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. *American Journal of Physiology-Heart and Circulatoy Physiology*, 293(1), H610-H619.

Rajesh, M., P. Mukhopadhyay, G. Hasko, J. W. Huffman, K. Mackie, & P. Pacher (2008). CB2 cannabinoid receptor agonists attenuate TNF-a-induced human vascular smooth muscle cell proliferation and migration. *British Journal of Pharmacology*, 153, 347-357.

Richardson, Denise, Richard G. Pearson, M. Liaque Latif, Michael J. Garle, David A. Barrett, David A. Kendall, Brigitte E. Scammell, Alison J. Reeve, & Victoria Chapman (2008). Characterisation of the cannabinoid system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Research & Therapy*, 10(2), 1-14.

Robles, E. M. Sanchez, A..Bagues Arias, & M. I. Martin Fontelles (2012). Cannabinoids and muscular pain. Effectiveness of the local administration in rat. *European Journal of Pain*, 16, 1116-1127.

Schuelery, Niklas, Michael P. Johnson, Jennifer L. Oskins, Karandeep Jassal, Mark G. Chambers, & Jason J. McDougall (2011). Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. *PAIN*, 152, 975-981.

Sumariwalla, Percy, Ruth Gallily, Susanna Tchilibon, Ester Fride, Raphael Mechoulam, & Marc Feldmann (2004). A novel synthetic, cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis. *Arthritis & Rheumatism*, 50(3), 985-998.

Watkins, Bruce A., Heather Hutchins, Yong Li, & Mark F. Seifert (2010). The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. *Journal of Nutritional Biochemistry*, 21, 1141-1152.

Whyte, L. S., L. Ford, S. A. Ridge, G. A. Cameron, M. J. Rogers, & R. A. Ross (2011). Cannabinoids and bone: endocannabinoids modulate human osteoclast function *in vitro*. *British Journal of Pharmacology*, 165, 2584-2597.

Chapter V: Cardiovascular Health and Cardiovascular Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the cardiovascular system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the cardiovascular system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the cardiovascular system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for cardiovascular disorders.

The Endocannabinoid System and THC and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, heart, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, diabetes has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of atherosclerosis, which affects the vascular system, supports adding the category of acquired as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the cardiovascular system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has anxiolytic and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert

antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of cardiovascular disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects which are beneficial in the prevention and management of certain cardiovascular disorders.

Human Cardiovascular System
The cardiovascular system is comprised of the heart and circulatory system. The endocannabinoid system interfaces with the cardiovascular system, mainly via CB1 receptors. Perfusion, cardiac output, blood pressure, and vessel patency are all influenced by the endocannabinoid system within the cardiovascular system. The intrinsic relationship between the two becomes evident in the development of abnormalities of the cardiovascular and circulatory systems, including cardiac arrhythmias, atherosclerosis, and myocardial ischemia. Clinical endocannabinoid deficiency (CECD) affects the function of the heart and cannabidiol (CBD) is currently being evaluated as a pharmaceutical in certain cardiac disorders.

Cardiovascular Disorders and Diseases: Atherosclerosis
Atherosclerosis, which reduces increases the risk of stroke, myocardial infarction, and hypertension, is directly related to the clinical endocannabinoid deficiency (CECD) and dysfunctional response of the immune system to the presence of endothelial adhesion molecules. The CB2 receptors located throughout the circulatory system regulate immune responses. Research indicates that phytocannabinoids, such as cannabidiol (CBD), reduce inflammatory responses to the presence of abnormal endothelial molecules and also reduce reactive oxidative stress (ROS), which is associated with cell death. CBD, therefore, as a potent anxiolytic, is suggested for the prevention of atherosclerosis, a disorder with basis in genetic and acquired Clinical Endocannabinoid Deficiency (CECD). THC in low doses may increase circulatory blood flow, thereby increasing oxygenation, supporting the use of CBD/THC in atherosclerosis management.

Cardiomyopathy
Cardiomyopathy is characterized by decreased diastolic and systolic myocardial performance and is associated with increased oxidative stress and expression of adhesion molecules. Vascular adhesion molecules increase fibrosis and connective tissue proliferation, ultimately culminating in cell death. Cardiomyopathy is considered an acquired clinical endocannabinoid deficiency (CECD) and is often associated with diabetes mellitus and metabolic syndrome. Research supports that CB1 and CB2 receptors respond to cannabidiol (CBD) in cardiomyopathy, improving cardiac dysfunction, reducing oxidative stress and associated cell death, and reducing inflammatory response by improving CB2 receptivity via increased

anandamide levels. Reduction in fibrosis was likewise associated with cannabidiol (CBD) administration, supporting the importance of improved cellular glucose usage in such conditions as diabetes and hyperinsulinemia, which thereby improves cardiomyopathy associated with these disorders. In primary cardiomyopathy, benefits are likewise reflected, warranting consideration of cannabidiol (CBD) supplementation.

Hypertension

Hypertension, in which circulating blood pressure exceeds human physiological normatives, is associated with cerebral vascular incident, dementia, myocardial infarction, and peripheral vascular disease. As both acquired and genetic clinical endocannabinoid deficiency (CECD), affecting CB1 and CB2 receptors throughout the body, hypertension is affected by reduced circulating cannabinoids. Administration of cannabidiol (CBD) increases anandamide levels, a lipid neurotransmitter that binds with CB1 and CB2 receptors directly, which correlates with relaxation of blood vessels and corresponding reduction in systemic blood pressure. Cannabidiol (CBD) supplementation is therefore supported for individuals at risk for malignant hypertension and adjunctively for individuals diagnosed and treated with hypertension, as deemed appropriate by the attending physician.

Myocardial Ischemia

Myocardial ischemia refers to the restriction of blood supply to the heart, reducing the oxygen and glucose required for cellular function. As a result of myocardial ischemic incidences, damage to the tissue of the myocardium occurs and is demonstrable through electrocardiogram and echocardiogram. Associated with acquired clinical endocannabinoid deficiency (CECD), myocardial ischemia is associated with decreased available cannabinoids to both CB1 and CB2 receptors located in the cardiac muscle. Research indicates that administration of cannabidiol (CBD) improves outcome in myocardial ischemia, reducing residual damage, and may be indicated preventatively in individuals with diabetes, hypertension, and atherosclerosis to prevent or reduce the severity of myocardial ischemic episodes.

Myocardial Infarction

Myocardial infarction refers to the cessation of blood flow to a portion of the cardiac muscle, with associated oxygen reduction, and damage to the myocardial tissue. Blockage of a coronary artery is commonly associated with myocardial infarction, which may or may not proceed to cardiac arrest and possible death. The accumulation of blood cells and cholesterol, and subsequent immune response, which adds further blockage within a coronary artery, contributes to the likelihood of myocardial infarction. Endocannabinoid receptors in the myocardial tissue, both CB1 and CB2, are affected by clinical endocannabinoid deficiency. Research indicates that the administration of cannabidiol (CBD) improved outcome in myocardial infarction and in prevention of atherosclerosis, which is associated with myocardial infarction. Cannabidiol (CBD) reduced inflammation and abnormal immunological response within the coronary arteries, reducing the likelihood of endothelial wall plaque formation. Adjunctive administration of cannabidiol is warranted for consideration in the management and prevention of myocardial infarction and associated cell death.

Endocannabinoid Deficiency (CECD) Classification: Cardiovascular Disorders

Disorder	Origin of CECD
Atherosclerosis	Acquired
Cardiomyopathy	Acquired
Hypertension	Genetic, Acquired
Myocardial Ischemia	Acquired
Myocardial Infarction	Acquired

CEN Medical Cannabis Pharmacological Prescription and Coding System:
Cardiovascular Disorder Application

The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Cannabis sativa must be used carefully in cardiovascular diseases involving arrhythmias and tachycardia. For peripheral vascular disease, THC may be useful in pain reduction.

Harry Thomas
DOB: 06-07-1946
Diagnosis: Peripheral Vascular Disease, ICD-9, 443.9
CS: 6.5%/6.5%
Use via vaporizer every six hours as needed for pain.
John Young, M.D.

Purchase of CBD oil may be completed online. Purchase of cannabis sativa may be done at dispensary with presentation of the prescription.

Composition Assignments

1. Please answer the following question. Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with angina.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the cardiovascular system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Andrag, Ellen & Michael J. Curtis (2013). Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids. *British Journal of Pharmacology*, 169, 1840-1848.

Bátkai, Sándor & Pál Pacher (2009). Endocannabinoids and cardiac contractile function: pathophysiological implications. *Pharmacology Research*, 60(2), 99-106.

Bátkai, Sándor, Pál Pacher, Douglas Osei-Hyaiman, Svetlana Radaeva, Jie Liu, Judith Harvey-White, László Offertáler, Ken Mackie, Audrey Rudd, Richard D. Bukowski, & George Kunos (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. *Circulation*, 110(14),1996-2002.

Booz, George (2008). CB1 cannabinoid receptor inhibition: promising approach for heart failure? *Congestive Heart Failure*, 14(6), 330-334.

Cappellano, Giuseppe, Francesca Uberti, Philippe Primo Caimmi, Stefano Pietronave, David A. S. G. Mary, Chiara Dianzani, Ezio Micalizzi, Matteo Melensi, Renzo Boldorini, Gabriella Nicosia, Enrico Crosio, Annalisa Chiocchetti, Franco Aina, Maria Prat, Umberto Dianzani, Giovanni Vacca, Cristiano Ariatti, & Elena Grossini (2013). Different expression and function of the endocannabinoid system in human epicardial apidose tissue in relation to heart disease. *Canadian Journal of Cardiology*, 29, 499-509.

Durst, Ronen, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, & Chaim Lotan (2007). Cannabidiol, a nonpsychoactive *Cannabis* constituent, protects against cardial ischemic reperfusion injury. *American Journal of Heart and Circulatory Physiology*, 293, H3602-H3607.

Durst, Ronen & Chaim Lotan (2011). The potential for clinical use of cannabinoids in treatment of cardiovascular diseases. *Cardiovascular Therapeutics*, 29(1), 17-22.

Hiley, C. Robin (2009). Endocannabinoids and the heart. *Journal of Cardiovascular Pharmacology*, 53(4), 267-276.

Hiley, C. Robin & William R. Ford (2003). Endocannabinoids as mediators in the heart: a potential target for therapy of remodeling after myocardial infarction? *British Journal of Pharmacology*, 138, 1183-1184.

Ho, W-S. Vanessa & Sheila M. Gardiner (2009). Acute hypertension reveal s depressor and vasodilator effects of cannabinoids in conscious rats. *British Journal of Pharmacology*, 156, 94-104.

Hoi, P. M., C. Visintin, M. Okuyama, S. M. Gardiner, S. S. Kaup, T. Bennett, D. Baker, D. L. Selwood, & C. R. Hiley (2007). Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide (VSN16) in the rat. *British Journal of Pharmacology*, 152, 751-764.

Ibrahim, Baddr M. & Abdel A. Abdel-Rahman (2014). Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: a review. *Journal of Advanced Research*, 5, 137-145.

Lagneux, Caroline & Daniel Lamontagne (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. *British Journal of Pharmacology*, 132, 793-796.

Lépicier, Philippe, Jean-François Bouchard, Caroline Lagneux, & Daniel Lamontagne (2003). Endocannabinoids protect the rat isolated heart against ischaemia. *British Journal of Pharmacology*, 139-805-815.

Liao, Yulin, Jianping Bin, Masanori Asakura, Wanling Xuan, Baihe Chen, Qiaobing Huang, Dingli Xu, Catherine Leddent, Seiji Takashima, & Masafumi Kitakaze (2012). Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. *European Heart Journal*, 33, 3124-3133.

Mach, F. F. Montecucco, & S. Steffens (2008). Cannabinoid receptors in acute and chronic complications of artherosclerosis. *British Journal of Pharmacology*, 153, 290-298.

Malinowska, Barbara, Marta Baranowska-Kuczko, & Eberhard Schilicker (2012). Triphasic blood pressure responses to cannabinoids: do we understand the mechanism. *British Journal of Pharmacology*, 165, 2073-2088.

Martin, Billy R. (2005). Role of lipids and lipid signaling in the development of cannabinoid tolerance. *Life Sciences*, 77, 1543-1558.

Mendizabál, V. E. & E. Adler-Graschinsky (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusion. *British Journal of Pharmacology*, 151, 427-440.

Montecucco, Fabrizio & Vincenzo di Marzo (2012). At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends *in Pharmacological Sciences*, 33(6), 331-340.

Montecucco, Fabrizio, Isabel Matias, Sébastien Lenglet, Stefania Petrosino, Fabienne Burger, Graziano Pelli, Vincent Braunersreuther, François Mach, Sabine Steffens, & Vincenzo di Marzo (2009). Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with artherosclerosis. *Atherosclerosis*, 205, 433-441.

Mukhopadhyay, Partha, Béla Horváth, Mohanraj Rajesh, Shingo Matsumoto, Keita, Saito, Sándor Bátkai, Vivek Patel, Galin Tanchian, Rachel Y. Gao, Benjamin F. Cravatt, György, Haskó, & Pál Pacher (2011). Fatty acid amide hydrolase is a key regulator of the endocannabinoid-induced myocardial tissue injury. *Free Radical Biology and Medicine*, 50(1), 179-195.

Mukhopadhyay, Partha, Mohanraj Rajesh, Sándor Bátkai, Vivek Patel, Yoshihiro Kashiwaya, Lucas Liaudet, Oleg V. Evgenov, Ken Mackie, György Haskó, & Pál Pacher (2010). CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. *Cardiovascular Research*, 85, 773-784.

Nodari, Savina, Alessandra Manerba, Marco Metra, & Livio dei Cas (2007). Endocannabinoids and cardiovascular prevention: real progress? *Heart International*, 3(1-2), 27-34.

O'Sulliva, Saoirse E., Patrick J. Kendall, & David A. Kendall (2012). Endocannabinoids and the cardiovascular response to stress. *Journal of Psychopharmacology*, 26(1), 71-82.

O'Sullivan, Saoirse E., Yan Sun, Andrew J. Bennett, Michael D. Randall, & David A. Kendall (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. *European Journal of Pharmacology*, 612, 61-68.

Pacher, P., S. Bátkai, & G. Kunos (2005). Cardiovascular pharmacology of cannabinoids. *Handbook of Experimental Pharmacology*, 168, 599-625.

Pacher, Pál, Sándor Bátkai, & George Kunos (2005). Blood pressure regulation by endocannabinoids and their receptors. *Neuropharmacology*, 48(8), 1130-1138.

Pacher,Pál, Sándor Bátkai, & George Kunõs (2005). Cirrhotic cardiomyopathy: an endocannabinoid connection? *British Journal of Pharmacology*, 146, 313-314.

Pacher, Pál & Sabine Steffens (2009). The emerging role of the endocannabinoid system in cardiovascular disease. *Seminars in Immunopathology*, 31(1), 63-77.

Rajesh, Mohanraj, Partha Mukhopadhyay, Sándor Bátkai, Vivek Patel, Keito Saito, Shingo Matsumoto, Yoshihiro Kashiwaya, Béla Horváth, Bani Mukhopadhyay, Lauren Becker, György Haskó, Lucas Liaudet, David A. Wink, Aristidis Veves, Raphael Mechoulam, & Pál Pacher (2010). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. *Journal of the American College of Cardiology*, 56(25), 2115-2125.

Rajesh, Mohanraj, Partha Mukhopadhyay, György Haskó, Lucas Liaudet, Ken Mackie, & Pál Pacher (2010). Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and –independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. *British Journal of Pharmacology*, 160, 688-700.

Robbins, Nathan, Sheryl E. Koch, & Jack Rubinstein (2013). Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease. *Translational Research*, 161(6), 469-476.

Rossmeisl, Martin, Zuzana Macek Jilkova, Ondrej Kuda, Tomas Jelenik, Sada Medrikova, Barbora Stankova, Björn Kristinsson, Gudmundur G. Haraldsson, Harald Svensen, Irin Stoknes, Peter Sjövall, Yiva Magnusson, Michiel G. J. Balvers, Kitty C. M. Verhoeckx, Eva Tvrzicka, Morten Bryhn, & Jan Kopecky (2012). Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high fat diet: possible role of endocannabinoids. *PLos ONE*, 7(6), 1-13.

Sarzani, S. (2008). Endocannabinoids, blood pressure and the human heart. *Journal of Neuroendocrinology*, 20(s1), 58-62.

Singla, Sandeep, Rajesh Sachdeva, & Jawahar L. Mehta (2012). Cannabinoids and atherosclerotic coronary heart disease. *Clinical Cardiology*, 35(6), 329-335.

Stanley, Christopher P., William H. Hind, & Saoirse E. O'Sullivan (2012). Is the cardiovascular system a therapeutic target for cannabidiol? *British Journal of Clinical Pharmacology*, 75(2), 313-322.

Stanley, Christopher & Saoirse E. O'Sulliva (2014). Vascular targets for cannabinoids: animal and human studies. *British Journal of Pharmacology*, 171(6), 1361-1378.

Steffens, Sabine & Pál Pácher (2012). Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. *British Journal of Pharmacology*, 167, 313-323.

Szmitko, Paul E. & Subodh Verma (2008). The endocannabinoid system and cardiometabolic risk. *Artherosclerosis*, 199, 248-256.

Tonstad, Serena (2006). Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. *Nutrition, Metabolism, & Cardiovascular Diseases*, 16, 156-162.

Underdown, Nichola J., C. Robin Hiley, & William R. Ford (2005). Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfuxio by a novel cannabinoid mechanism. *British Journal of Pharmacology*, 146, 809-816.

Walsh, Sarah K., Claire Y. Hepburn, Kathleen A. Kane, & Cherry L. Wainwright (2010). Acute administration of cannabidiol in vivo suppresses ischemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. *British Journal of Pharmacology*, 160, 1234-1242.

Wang, Peng-Fei, Li-Sheng Jiang, Jun Bu, Xiao-Jin Huang, Wei Song, Yong-Ping Du, & Ben He (2012). Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. *Journal of Cardiovascular Pharmacology*, 59, 301-307.

Weis, Florian, Andres Beiras-Fernandez, Ralf Sodian, Ingo Kaczmarek, Bruno Reichart, Andres Beiras, Gustav Schelling, & Simone Kreth (2010). Substantially altered expression pattern of cannabinoid receptor 2 activated endocannabinoid system in patients with severe heart failure. *Journal of Molecular and Cellular Cardiology*, 48, 1187-1193.

Wheal, A. J., T. Bennett, M. D. Randall, & S. M. Gardiner (2007). Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. *British Journal of Pharmacology*, 152, 717-724.

Chapter VI: Pulmonary Health and Pulmonary Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the pulmonary system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the pulmonary system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the pulmonary system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for pulmonary disorders.

The Endocannabinoid System and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, asthma has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of neoplastic disease of the lung supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the pulmonary system, which is directly affected by the immunological, cardiovascular, and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has anti-tumoral and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol

(CBD) has been demonstrated to cross the blood-brain barrier and exert antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of pulmonary disorders.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects which are beneficial in the prevention and management of certain pulmonary disorders.

Human Pulmonary System
The pulmonary, or respiratory, system of specific organs executes the process by which oxygen and carbon dioxide are exchanged with external air. The lungs, trachea, bronchi, and diaphragm facilitate respiration and gaseous exchange, which facilitates oxygenation of the blood through diffusion.

The endocannabinoid system is critical in facilitating the ability of the lungs to execute respiration. CB1 and CB2 receptors are dispersed throughout the respiratory system and research indicates that clinical endocannabinoid deficiencies contribute to the development of chronic and malignant pulmonary diseases.

Pulmonary Disorders and Diseases: Asthma
Asthma is an inflammatory disease of the respiratory system, which causes shortness of breath and reduced tidal volumes of the lungs. Reactive airway disease accompanies asthma, which is chronic, but can rapidly become fatal without intervention. The endocannabinoid system is critical in managing the inflammatory response in asthma via CB1 and CB2 receptors. CB1 receptors activate bronchodilator effects by relaxing smooth muscle, thereby easing respiratory distress. CB2 receptors control immunological response in the lungs and the endocannabinoid system modulates the potential hyperactive response to an antigen. Clinical endocannabinoid deficiency (CECD) associated with asthma is both genetic and idiopathic autoimmune. Research indicates that elevating anandamide levels in the pulmonary system, via the intake of cannabidiol, reduced morbidity associated asthma by modulating the inflammatory response in asthma.

Emphysema
Emphysema, or Chronic Obstructive Pulmonary Disease (COPD), is a progressive disease of the lungs which restricts oxygenation and perfusion, thereby affecting not only the respiratory system, but also the cardiovascular and neurological systems. Clinical Endocannabinoid Deficiency (CECD) associated with emphysema is acquired, reflecting the increased incidence secondary to cigarette smoking. CB1 and CB2 receptors in the respiratory tract respond favorably to cannabidiol in clinical research, reducing chronic inflammation of the lungs and

inducing bronchodilation, which increases oxygenation. Cannabidiol (CBD) and THC possess anxiolytic and anti-inflammatory properties, and are warranted in emphysema to increase tidal volume and reduce inflammatory processes of the lung.

Lung Cancer

Lung cancer is an acquired malignancy that is most commonly associated with cigarette smoking. Genetic malformations occur early on in the use of tobacco and the development of malignancy may not occur until decades later. The endocannabinoid system is critical in maintaining homeostasis of the immunological system and both CB1 and CB2 receptors are affected by tobacco use. The acquired clinical endocannabinoid deficiency (CECD) associated with lung cancer, non-small cell and small cell alike, responds to the administration of cannabidiol (CBD) in clinical research. CBD oil with THC also inhibits metastasis of lung cancer, which commonly spreads to the brain and spine. Preventively, cannabidiol (CBD) is recommended in individuals who may be at risk for lung cancer, including those who have been exposed to second-hand smoking. In treatment, adjunctive therapy with cannabidiol (CBD) and THC may inhibit metastasis from primary lung tumors.

Pneumonia (Interstitial)

Pneumonia, associated with bacteria or viral infections, causes respiratory dysfunction and often distress in individuals with underlying autoimmune diseases, such as multiple sclerosis. Clinical endocannabinoid deficiency (CECD) associated with pneumonia affects CB2 receptors, which regulate immunological responses. Indeed, CECD deficiency may cause hyperactivity of certain white cells, which then further inhibit respiratory function. Cannabidiol (CBD) possesses antibacterial and anti-inflammatory properties, which may augment the benefit of antibiotic and steroidal therapies in the management of pneumonia. In individuals at increased risk for pneumonia, supplementation with cannabidiol routinely increases circulating anandamide, which then binds directly to CB2 receptors. In combination with preventative health practices, the addition of cannabidiol (CBD) may reduce the incidence or severity of the occurrence of bacterial and/or viral infections associated with pneumonia.

Pulmonary Hypertension

Pulmonary hypertension is a chronic and potentially life-threatening disorder, which increases the pulmonary artery pressure, increasing the likelihood of vessel rupture and mortality. Cannabidiol (CBD) induces relaxation of vessel walls, lowering systemic blood pressure. Research indicates administration of cannabidiol (CBD) in pulmonary hypertension significantly reduced pulmonary artery pressure by affecting CB1 binding abilities. In combination with treatment, supplementation with cannabidiol (CBD) is suggested in individuals at-risk or diagnosed with pulmonary hypertension.

Endocannabinoid Deficiency (CECD) Classification: Pulmonary Disorders

Disorder	Origin of CECD
Asthma	Genetic
Emphysema	Acquired
Lung Cancer	Acquired
Pneumonia	Acquired
Pulmonary Hypertension	Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System
Pulmonary Disorder Application
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

THC may be recommended for pulmonary disorders including COPD and asthma to relieve anxiety.

The prescription would read:
Ray Monty
DOB: 12-13-56
Diagnosis: COPD, ICD-9 492
CS: 14-16%/6-9%
Use via vaporizer every six hours as needed.
Frank Jayne, M.D.

Composition Assignments
1. Please answer the following question. Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with non-small cell lung cancer.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the pulmonary system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Athanasius, Adriana, Anna B. Clarke, Amy E. Turner, Nether M. Kumara, Sara Vakilpour, Paul A. Smith, Dmitra Bagiokou, Tracey D. Bradshaw, Andrew D. Westwell, Lin Fang, Dileep N. Lobo, Cris S. Constantinescu, Vittorio Calabrese, Andrzej Loesch, Stephen P. H. Alexander, Richard H. Clothier, David A. Kendall, & Timothy E. Bates (2007). Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. *Biochemical and Biophysical Research Communication*, 364, 131-137.

Baranowska-Kuczko, Marta, Margaret R. MacLean, Hanna Kozlowska, & Barbara Malinowski (2012). Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. *Pharmacological Research*, 66, 251-259.

Brown, Iain, Maria G. Cascio, Dino Rotondo, Roger G. Pertwee, Stephen D. Heys, & Klaus W. J. Wahle (2013). Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. *Progress in Lipid Research*, 52, 80-109.

Cui, Yong-Yao, Bruno D'Agostino, Paul-Andre Risse, Guiseppina Marrocco, Emmanuel Naline, Yong Zhang, Hong-Zhuan Chen, Olivier Finance, Murielle Rinaldi-Carmona, Francesco Rossi, & Charles Advenier (2007). Cannabinoid CB2 receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. *European Journal of Pharmacology*, 573, 206-213.

Dudasova, A., S. D. Keir, M. E. Parsons, A. Mollerman, & C. P. Page (2013). The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig. *Pulmonary Pharmacology & Therapeutics*, 26, 373-379.

Engels, Frederike K., Floris A. de Jong, Ron H. J. Mathijssen, Joelle A. Erkens, Ron M. Herings, & Jaap Verweij (2007). Medicinal cannabis in oncology. *European Journal of Cancer*, 43, 2638-2644.

Kapoor, Shailendra (2013). The inhibitory effects of cannabidiol on systemic malignant tumors. *Journal of Pain and Symptom Management*, 45(4), 1.

Kozlowska, H., M. Baranowska, E. Schlicker, M. Kozlowski, J. Laudanski, and B. Malinowska (2008). Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. *British Journal of Pharmacology*, 155, 1034-1042.

Pan, Hao, Partha Mukhopadhyay, Mohanraj Rajesh, Vivek Patel, Bani Mukhopadhyay, Bin Gao, Gyorgy Hasko, & Pal Pacher (2009). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress inflammation and cell death. *The Journal of Pharmacology and Experimental Therapeutics*, 328, 708-714.

Pickering, Elspeth E., Stephen J. Semple, Muhammad S. Nazir, Kevin Murphy, Thomas M. Snow, Andrew R. Cummin, Shakeeb H. Moosavi, Abraham Guz, & Anita Holdcraft (2011). Cannabinoid eefcts on ventilation and breathlessness: a pilot study of efficacy and safety. *Chronic Respiratory Disease*, 8(2), 109-118.

Prett, A., R. K. Ganju, & J. E. Groopman (2008). Δ9-tetrahydrocannabidiol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. *Oncogene*, 27, 339-346.

Preet, Anju, Zahida Qamri, & Mohd W. Nasser (2011). Cannabinoid receptor, CB1 and CB2, as novel targets for inhibition of non-small cell lung growth and metastasis. *Cancer Prevention Research*, 4, 65-75.

Ramer, Robert, Katharina Bublitz, Nadine Freimuth, Jutta Merkord, Helga Rohde, Maria Haustein, Philipp Borchert, Ellen Schmuhl, Michael Linnebacher, & Burkhard Hinz (2012). Cannabidiol inhibits lung cancel invasion and metastasis via intercellular adhesion molecule-1. *Federation of American Societies for Experimental Biology*, 26, 1535-1548.

Ramer, Robert, Sasha Fischer, Maria Haustein, Katrin Manda, & Burkhard Hinz (2014). Cannabinoids inhibit andiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. *Biochemical Pharmacology*, 91, 202-216.

Ramer, Robert, Anja Rohde, Jutta Merkord, Helga Rohde, & Burkhard Hinz (2010). Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. *Pharmaceutical Research*, 27, 2162-2174.

Ribeiro, Alison, Viviane Ferraz-de-Paula, Milena L. Pinheiro, Luana B. Vitoretti, Domenica P. Mariano-Souza, Wanderley M. Quinteiro-Filho, Adriana T. Akamine, Vinicus I. Almeida, Joao Quevedo, Felipe Dal-Pizzol, Jaime E. Hallak, Antonio W. Zuardi, Jose A. Crippa, & Joao Palermo-Neto (2012). Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A2a receptor. *European Journal of Pharmacology*, 678, 78-85.

Rice, Ward, John M. Shannon, Fannie Burton, & Dana Fiedeldey (1997). Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. *European Journal of Pharmacology*, 327, 227-232.

Sarfaraz, Sami, Vaqar M. Adhami, & Deeba N. Syed (2008). Cannabinoids for cancer treatment. *Cancer Research*, 68, 339-342.

Velasco, Guillermo, Cristina Sanchez, & Manuel Guzman (2012). Towards the use of cannabinoids as antitumor agents. *Nature*, 12, 436-444.

Chapter VII: Dermatological Health and Dermatological Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the dermatological system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the dermatological system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the dermatological system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for dermatological disorders.

The Endocannabinoid System and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems, as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency relates to hereditary acquisition of a disorder, acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, dermatitis has been associated with endocannabinoid deficiency (CECD) and the disease is often categorized as acquired, originating from an extrinsic source. The presentation of scleroderma, which is multisystemic, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the dermatological system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has analgesic, anti-tumoral, and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert

antioxidant, antimicrobial, and antitumoral properties, rendering it valuable in the prevention and treatment of oxidative dermatologic disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects, which are beneficial in the prevention and management of certain dermatological disorders.

Human Dermatological System
The largest organ of the human body is the skin, which protects and armors the underlying adipose tissue, muscle, ligaments, viscera, and skeletal system. Multiple layers of ectodermal tissue facilitate insulation, temperature regulation, sensation and synthesis of vitamin D and B for the human body. As the initial line of defense, the skin protects the body from pathogens and minimizes dehydration, managing water loss. Pigmentation of the skin varies in the world and originated from geographical location and climate category.

The endocannabinoid system facilitates immunological and nervous system responses throughout the dermatological system via CB1, autonomically through CB1 receptors, and immunologically through CB2 receptors. Various manifestations of endocannabinoid deficiency affect the dermatological structures, increasing the incidence of diseases which affect the skin and underlying tissues

Dermatological Disorders and Diseases: Dermatitis
Chronic dermatological conditions, such as psoriasis, and acute conditions, such as contact dermatitis, cause rash, pruritus, increased risk of infection, and psychological stress. The immunological response often increases symptoms associated with dermatitis. CB1 and CB2 receptors in genetic and acquired clinical endocannabinoid deficiency (CECD) in dermatitis respond to the administration of cannabidiol (CBD). Research indicates that cannabidiol (CBD) possesses anti-inflammatory and analgesic properties, which reduce symptoms. Further, the increased uptake of administered cannabidiol (CBD) has been found to regulate the immunological responses to dermatitis, thereby improving symptoms and reducing anxiety and depression associated with dermatitis. Cannabidiol (CBD) is suggested as adjunctive therapy in the management of both chronic and acute dermatitis.

Diabetic Ulcer
Diabetic ulceration occurs when decreased circulatory perfusion accompanies diabetes. Reduced blood flow to the periphery, including legs and feet, causes chronic ulceration, cellulitis and recurring infection. Clinical endocannabinoid deficiency (CECD) in diabetes mellitus responds to adjunctive administration of CBD oil with oral hypoglycemic agents and insulin. CB1 and CB2 receptors are restored with cannabidiol (CBD) administration, reducing sensory and

dysfunctional immunological responses, respectively. Cannabidiol (CBD) possesses anti-inflammatory and anti-bacterial properties, which potentiate therapeutic healing options, such as hyperbaric oxygen therapy, in the management of diabetic ulcerations.

Scleroderma

Scleroderma, a systemic autoimmune disorder manifesting initially, and most frequently, as a dermatologic exacerbation, causes hardening of the skin and tissues. Alterations in oxygen perfusion and aberrant immunological responses contribute to symptoms of pain and fatigue. Clinical endocannabinoid deficiency (CECD) in scleroderma is considered idiopathic autoimmune, affecting CB1 and CB2 receptors throughout the human body. Administration of cannabidiol (CBD) has been shown to improve skin elasticity, reduce dermatological exacerbations, and relieve discomfort associated with this chronic disorder.

Skin Cancer

Malignancy of the skin includes such malignancies as squamous cell carcinoma and malignant melanoma. Tumoral growth and visceral dissemination of malignancy characterizes carcinoma of the skin, categorized as acquired and idiopathic autoimmune clinical endocannabinoid deficiency (CECD). Administration of cannabidiol (CBD) triggers malignant cell death, inhibiting tumor growth, and metastasis to viscera. Further, autophagy, which removes cellular waste, is enhanced by cannabidiol (CBD), expediting malignant cell death.

Administration of cannabidiol (CBD) is warranted given conclusive research which supports anti-tumoral, anti-bacterial, and analgesic effects of CBD oil.

Endocannabinoid Deficiency (CECD) Classification: Dermatological Disorders

Disorder	Origin of CECD
Dermatitis	Genetic, Acquired
Diabetic Ulcer	Acquired
Scleroderma	Idiopathic Autoimmune
Skin Cancer	Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System
Dermatological Disorder Application

The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

The prescription for use in malignant melanoma may read as follows:

Gertrude Folsom
DOB: 4-5-1978
Diagnosis: Malignant Melanoma, ICD-9: 172.9
CS: 15-17%/0-1%
Use via vaporizer every four hours as needed.
Bert Maonet, M.D.

Composition Assignments
1. Please answer the following question. Cannabidiol (CBD) is a suitable adjunctive therapy for the patient with cellulitis.
    a. True
    b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the dermatological system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
    a. Author and affiliation
    b. Study population
    c. Purpose
    d. Outcome of the study
    e. Importance of the research

Bibliography

Balistreri, Epifania, Estrella Garcia-Gonzalez, Enrico Selvim, Alfiya Akhmetshina, Katrin Palumbo, Sauro Lorenzini, Roberta Maggio, Monica Lucattelli, Mauro Galeazzi, & Jorg W. H. Distler (2011). The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. *Annals of the Rheumatic Diseases*, 70(4), 695-699.

Bíró, Tamás, Balázs I. Tóth, György Haskó, Ralf Paus, & Pál Pacher (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic perspectives. *Trends in Pharmacological Science*, 30(8), 411-420.

Casanova, M. Llanos, Cristina Blázquez, Jesús Martinez-Palacio, Concepción Villanueva, M. Jesus Fernández-Aceñero, John W. Huffman, José L. Jorcano, & Manuel Guzmán (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *Journal of Clinical Investigation*, 111(1), 43-50.

Csóka, Balázs, Zoltán H. Náméth, Partha Mukhopadhyay, Zoltán Spolarics, Mohanraj Rajesh, Stephanie Federici, Edwin A. Deitch, Sándor Bátkai, Pál Pacher, & György Haskó (2009). CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. *PLos One*, 4(7), e6409.

Czifra, Gabriella, Attila G. Szöllösi, Balázs I. Tóth, Julien Demaude, Charbel Bouez, Lionel Breton, & Tamás Bíró (2012). Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells. *Journal of Investigative Dermatology*, 132, 1967-1976.

Gaffal, Evelyn, Nicole Godde, Mira Jakobs, Tobias Bald, & Thomas Tüting (2014). Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis. *Experimental Dermatology*, 23, 401-406.

Gaffal, Evelyn, Mira Cron, Nicole Grodde, Tobias Bald, Rohini Kuner, Andreas Zimmer, Beat Lutz, and Thomas Tüting (2013). Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. *The Journal of Immunology*, 190, 4929-4936.

Gertsch, Jürg, Marco Leonti, Stefan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Hartmann, Meliha Karsak, & Andreas Zimmer (2008). Beta-caryophyllene is a dietary cannabinoid. *Proceedings from the National Academy of Sciences*, 105(26), 9099-9104.

Jonsson, Kent-Olov, Emma Persson, & Christopher J. Fowler (2006). The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. *Life Sciences*, 78(6), 598-606.

Kim, Jee Young, Jiwon Gye, Ji-yeon Yoo, Hyun Jung Kim, Se Kyoo Jeong, Seung-Phil Hong, & Sung-Ku Ahn (2013). Expression of cannabinoid receptor type 1&2 in the normal and diseased skin. *Journal of Dermatological Science*, 69(2), e25.

Kremer, Andreas E., Jamison Feramisco, Peter W. Reeh, Ulrich Beuers, & Ronald P. J. Oude Elferink (2014). Receptors, cells and circuits involved in pruritis of systemic disorders. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, 1842(7), 869-892.

Leonti, Marco, Laura Casu, Stefan Raduner, Filippo Cottiglia, Constantino Floris, Karl-Heinz Altmann, & Jürg Gertsch (2010). Falcarinol is a covalent cannabinoid CB1 receptor agonist and induces pro-allergic effects in skin. *Biochemical Pharmacology*, 79, 1815-1826.

Lodzki, M., B. Godin, L. Rakou, R. Mechoulam, R. Gallily, & E. Touitou (2003). Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. *Journal of Controlled Release*, 93, 377-387.

Marquart, Sieglinde, Pawel Zerr, Alfiya Akhmetshina, Katrin Palumbo, Nicole Reich, Michal Tomcik, Angelika Horn, Clara Dees, Matthias Engels, Jochen Zwerina, Oliver Distler, Georg Schett, & Jörg H. W. Distler (2010). Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. *Arthritis & Rheumatism*, 62(11), 3467-3476.

Nakajima, Jun'ichi, Dai Nakae, & Ken Yasukawa (2013). Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumor promotion in mice. *Journal of Pharmacy and Pharmacology*, 65(8), 1223-1230.

Oláh, Attila, Balázs I. Tóth, István Borbíró, Koji Sugawara, Attila Szöllösi, Gabriella Czifra, Balázs Pál, Christos C. Zouboulis, Ralf Paus, & Tamás Bíró (2014). Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes. *Journal of Clinical Investigation*, 124(9), 3713-3724.

Paus, Ralf, Martin Schmelz, Tamás Bíró, & Martin Steinhoff (2006). Frontiers in pruritus research: scratching the brain for more effective itch therapy. *Journal of Clinical Investigation*, 116(5), 1174-1186.

Pérez-Gómez, E., C. Andradas, J. M. Flores, M. Quintanilla, J. M. Paramio, M. Guzmán, & C. Sánchez (2013). The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. *Oncogene*, 32, 2534-2542.

Pucci, Mariangela, Cinzia Rapino, Andrea di Francesco, Enrico Dainese, Claudio D'Addario, & Mauro Maccarrone (2013). Epigenetic control of skin differentiation genes by phytocannabinoids. *British Journal of Pharmacology*, 170, 581-591.

Ramot, Yuval, Koji Sugawara, Nóra Zákány, Balázs I. Tóth, Tamás Bíró, & Ralf Paus (2013). A novel control of human keratin expression: cannabinoid receptor-1 mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes *in vitro* and *in situ*. *Peer J*, 1, e40.

Robinson, Rebecca Hartzell, Joseph J. Meissler, Jessica M. Breslow-Deckmanm John Gaughan, Martin W. Adler, & Toby K. Eisenstein (2013). Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. *Journal of Neuroimmune Pharmacology*, 8, 1239-1250.ika, Diane Ros

Roelandt, Truus, Carol Heughebaert, Stephanie Bredif, Christina Giddelo, Caroline Baudouin, Philippe Msika, Diane Roseeuw, Yoshikazu Uchida, Peter M. Elias, & Jean-Pierre Hachem (2012). Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation. *Experimental Dermatology*, 21(9), 688-693.

Schäkel, Knut, Thomas Döbel, & Ina Bosselmann (2014). Future treatment options for atypical dermatitis-small molecules and beyond. *Journal of Dermatological Science*, 64(5), 91-100.

Schlosburg, Joel E., Dale L. Boger, Benjamin F. Cravatt, & Aron H. Lichtman (2009). Endocannabinoid modulation of scratching response in an acute allergenic mouse model: a new prospective neural therapeutic target for pruritus. *Journal of Pharmacology and Experimental Therapeutics*, 329(1), 314-323.

Servettaz, Amélie, Niloufar Kavian, Carole Nicco, Vanessa Deveaux, Christiane Chéreau, Andrew Wang, Andreas Zimmer, Sophie Lotersztajn, Bernard Weill, & Frédéric Batteux (2010). Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. *The American Journal of Pathology*, 177(1), 187-196.

Spradley, Jessica Marie, Auva Davoodi, Leland Bruce Gee, Jr, Mirela Iodi Carstens, & E. Carstens (2012). Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin. *Neuropharmacology*, 63(4), 743-749.

Ständer, Sonja, Martin Schmelz, Dieter Metze, Thomas Luger, & Roman Rukwied (2005). Distribution of cannabinoid receptor 1 (CB1) and receptor 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. *Journal of Dermatological Science*, 38, 177-188.

Sugawara, Koji, Tamás Bíró, Daisuke Tsuruta, Balázs I. Tóth, Amo Kromminga, Nóra Zákány, Anne Zimmer, Wolfgang Funk, Bernhard F. Gibbs, Andreas Zimmer, & Ralf Paus (2012). Endocannabinoids limit excessive mast cell maturation and activation in human skin. *Journal of Allergy and Clinical Immunology*, 129(3), 726-738.

Tóth, Balázs I., Nóra Dobrosi, Angéla Dajnoki, Gabriella Czifra, Attila Oláh, Attila Szöllösi, István Juhász, Koji Sugawara, Ralf Paus, & Tamás Bíró (2011). Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement cannabinoid receptor-1 and transient receptor potential vanilloid-1. *Journal of Investigative Dermatology*, 131, 1095-1104.

Zheng, Ji-Long, Tian-Shui Yu, Xiao-Na Li, Yan-Yan Fan, Wen-Xiang Ma, Yu Du, Rui Zhao, & Da-Wei Guan (2012). Cannabinoid receptor type 2 is time-dependently expressed during skin wound healing in mice. *International Journal of Legal Medicine*, 126(5), 807-814.

Chapter VIII: Endocrine Health and Endocrine Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the endocrine system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the endocrine system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the endocrine system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for endocrine disorders.

The Endocannabinoid System and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations.

Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of primary multifocal leukoencephalopathy (PML), which affects the neurological system, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the endocrine system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has neuroprotective and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors.

Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert antioxidant, antimicrobial, and neuroprotective properties, rendering it valuable in the prevention and treatment of oxidative endocrine disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects which are beneficial in the prevention and management of certain endocrine disorders.

Human Endocrine System
The endocrine system refers to the collection of glands of an organism that secrete hormones directly into the circulatory system to be carried towards a distant target organ. The major endocrine glands include the pineal gland, pituitary gland, pancreas, ovaries, testes, thyroid gland, parathyroid gland, hypothalamus, gastrointestinal tract and adrenal glands. The endocrine system is in contrast to the exocrine system, which secretes its hormones using ducts. The endocrine system is an information signal system like the nervous system, yet its effects and mechanism are classifiably different. The endocrine system's effects are slow to initiate, and prolonged in their response, lasting from a few hours up to weeks. The nervous system sends information very quickly, and responses are generally short lived. In vertebrates, the hypothalamus is the neural control center for all endocrine systems. The field of study dealing with the endocrine system and its disorders is endocrinology, a branch of internal medicine.

Special features of endocrine glands are, in general, their ductless nature, their vascularity, and commonly the presence of intracellular vacuoles or granules that store their hormones. In contrast, exocrine glands, such as salivary glands, sweat glands, and glands within the gastrointestinal tract, tend to be much less vascular and have ducts or a hollow lumen.
In addition to the specialized endocrine organs mentioned above, many other organs that are part of other body systems, such as bone, kidney, liver, heart and gonads, have secondary endocrine functions. For example the kidney secretes endocrine hormones such as erythropoietin and renin.

A number of glands that signal each other in sequence are usually referred to as an axis, for example, the hypothalamic-pituitary-adrenal axis. As opposed to endocrine factors that travel considerably longer distances via the circulatory system, other signaling molecules, such as paracrine factors involved in paracrine signaling diffuse over a relatively short distance.

Endocrine Disorders and Diseases: Diabetes

Diabetes is an endocrine disorder with a strong hereditary component, affecting children and adults throughout the lifespan. The development of insulin resistance and glucose dysregulation characterizes diabetes mellitus, affecting the cardiovascular, immunological, and neurological systems as well as the endocrine system. Clinical endocannabinoid deficiency (CECD), characterized as genetic and acquired, affects excitatory CB1 receptors and immune-responsive CB2 receptors in the endocrine system. Research supports the benefit of cannabidiol (CBD) in reducing insulin resistance and as a hypoglycemic agent. Preventatively in individuals at risk for diabetes mellitus, and as adjunctive therapy under physician supervision in management of serum glucose, cannabidiol is suggested to improve disease management and prevent secondary manifestations of the disease, such as diabetic neuropathy.

Hypothyroidism

Hypothyroidism is a disease that affects the thyroid glands ability to secrete associated hormones, leading to weight gain, fatigue, immune dysfunction, and internal temperature regulation dysfunction. Medical management includes hormonal supplementation, and cannabidiol (CBD) has been shown to improve symptoms of hypothyroidism as adjunctive therapy. CB1 receptors are directly affected in hypothyroidism, which is considered idiopathic autoimmune and genetic in relation to clinical endocannabinoid deficiency (CECD). In individuals at risk for the development of hypothyroidism, preventative administration is warranted to improve the function and receptivity of CB1 receptors to anandamide, the lipid neurotransmitter that is increased by CBD oil.

Thyroid cancer

Malignant tumors of the thyroid affect hormonal function, rendering the individual with profound symptoms of fatigue and depression. Clinical endocannabinoid deficiency (CECD) in thyroid cancer affects CB2 receptors, reducing the ability of the immune system to eradicate malignancy. The anti-tumoral benefits of cannabidiol (CBD) are well documented and administration is suggested as adjunctive therapy in the management of thyroid cancer. In patients at risk for developing thyroid cancer, associated with hypothyroidism, prophylactic use of cannabidiol may be considered to prevent thyroid dysfunction. Metastatic disease associated with cancer has been inhibited by the use of cannabidiol in human studies, suggesting beneficial use in diagnosed metastatic disease.   .

Endocannabinoid Deficiency (CECD) Classification: Endocrine Disorders

Disorder	Origin of CECD
Diabetes	Genetic
Hypothyroidism	Genetic
Thyroid cancer	Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System
Endocrine Disorder Application
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: Cannabis sativa for diabetes mellitus may be purchased at a dispensary. An example prescription follows:

Nancy Victorial
DOB: 08-09-1945
Diagnosis: Diabetes Mellitus, ICD-9: 250.00
CS: 18%/1-3%
Use via vaporizer every six hours as needed.
David Read, M.D.

Composition Assignments
1. Please answer the following question. Medical cannabis is a suitable adjunctive therapy for the patient with hypothyroidism.
    a. True
    b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the endocrine system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
    a. Author and affiliation
    b. Study population
    c. Purpose
    d. Outcome of the study
    e. Importance of the research

Bibliography

Asúa, Teresa, Ainhoa Bilboa, Miguel Angel Gorriti, Jose Antonio Lopez-Moreno, Maria del Mar Álvarez, Miguel Navarro, Fernando Rodríguez de Fonseca, Ana Perez-Castillo, & Angel Santos (2006). Implication of the endocannabinoid system in the locomotor hyper-activity associated with congenital hypothyroidism. *Endocrinology*, 149(5), 2657-2666.

Barutta, Federica, Alessandro Corbelli, Raffaella Mastrocola, Roberto Gambino, Vincenzo di Marzo, Silvia Pinach, Maria Pia Rastaldi, Paolo Cavallo Perin & Gabriella Gruden (2010). Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. *Diabetes*, 59, 1046-1054.

Bhargava, Hemendra N. & Anil Gulati (1988). Selective inhibition of the binding of 3H-(3-MeHis2)thyrotropin releasing hormone to rat amygdale membranes by some naturally occurring cannabinoids. *Peptides*, 9(4), 771-775.

Bifulco, Maurizio, Anna Maria Malfitano, Simona Pisanti, & Chiara Laezza (2008). Endocannabinoids in endocrine and related tumors. *Endocrine-Related Cancer*, 15, 391-408.

Breivogel, Christopher S. & Steven R. Childers (1998). The functional neuroanatomy of brain cannabinoid receptors. *Neurobiology of Disease*, 5(6), 417-431.

Cardinal, Pierre, Luigi Bellocchio, Samantha Clark, Astrid Cannich, Matthias Klugmann, Beat Lutz, Giovanni Masciano, & Daniela Cota (2012). Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. *Endocrinology*, 153(9), 4136-4143.

Dando, I., M. Donadelli, C. Costanzo, E. Dalla Pozza, A. D'Alessandro, L. Zolla, & M. Palmieri (2013). Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Citation: Cell Death and Disease*, 4, 1-10.

Deli, Levente, Gábor Wittman, Imre Kalló, Ronald M. Lechan, Masahiko Watanabe, Zsolt Liposits, & Csaba Fekete (2013). Type 1 cannabinoid receptor-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons. *Endocrinology*, 150(1), 98-103.

Farkas, Imre, Imre Kalló, Levente Deli, Barbara Vida, Erik Hrabovsky, Csaba Fekete, Suzanne M. Moenter, Masahiko Watanabe, & Zsoit Liposits (2013). Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. *Endocrinology*, 151(12),5818-5829.

Giné, Elena, Victor Echeverry-Alzate, Jose Antonio López-Moreno, Alejandro López-Jimenez, Daniel Torres-Romero, Ana Perez-Castillo, & Angel Santos (2013). Developmentally-induced hypothyroidism alters the expression of Egr-1 and Arc genes and the sensitivity to cannabinoid agonists in the hippocampus: possible implications for memory and learning. *Molecular and Cellular5 Endocrinology*, 365(1), 119-128.

Hill, Matthew N., Ryan J. McLaughlin, Anna C. Morrish, Victor Viau, Stan B. Floresco, Cecilia J. Hillard, & Boris B. Gorzaika (2009). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. *Neuropsychopharmacology*, 34(13), 2733-2745.

Horváth, Béla, Partha Mukhopadhyay, György Haskó, & Pál Pacher (2012). The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. *The American Journal of Pathology*, 180(2), 432-442.

Imbernon, Monica, Lauren Whyte, Adenis Diaz-Arteaga, Wendy R. Russell, Natalia R. Moreno, María J. Vazquez, Carmen R. Gonzalez, Alberto Díaz-Ruiz, Miguel Lopez, Maria M. Malagón, Ruth A. Ross, Carlos Dieguez, & Ruben Nogueiras (2014). Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. *Molecular and Cellular Endocrinology*, 383(1-2), 159-169.

Jonnalagadda, Venu Gopal, Allam Venkata Sita Ram Raju, Srinivas Pittala, Afsar shaik, & Nilakash Annaji Selkar (2014). The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. *Advanced Pharmaceutical Bulletin*, 4(3), 209-217.

Matias, Isabel, Stefania Petrosino, Alessandro Racioppi, Raffaele Capasso, Angelo A. Izzo, & Vincenzo di Marzo (2008). Dysregulation of peripheral endocannabinoid levels in hyper-glycemia and obesity: effect of high fat diets. *Molecular and Cellular Endocrinology*, 286S, S66-S78.

Michalski, Christoph W., Florian E. Oti, Mert Erkan, Danguole Sauliunaite, Frank Bergmann, Pal Pacher, Sandor Batkai, Michael W. Müller, Nathalia A. Giese, Helmut Friess, & Jörg Kleef (2008). Cannabinoids in pancreatic cancer: correlation with survival and pain. *International Journal of Cancer*, 122(4), 742-750.

Murphy, Laura L., Raúl M. Muñoz, Brian A. Adrian, & María A. Villanúa (1998). Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. *Neurobiology of Disease*, 5, 432-446.

Pagano, Claudio, Catia Pilon, Alessandra Calcagno, Riccardo Urbanet, Marco Rossato, Gabriella Milan, Katiuscia Bianchi, Rosario Rizzuto, Paolo Bernante, Giovanni Federspil, & Roberto Vettor (2007). The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. *The Journal of Clinical Endocrinology & Metabolism*, 92(12), 4810-4819.

Pagotto, Uberto, Giovanni Marsicano, Daniela Cota, Beat Lutz, & Renato Pasquali (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocrine Reviews*, 27(1), 73-100.

Pagotta, U., G. Marsicano, F. Fezza, M. Theodoropoulou, Y. Grübler, J. Stalla, T. Arzberger, A. Milone, M. Losa, V. di Marzo, B. Lutz, & G. K. Stalla (2001). Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. *The Journal of Clinical Endocrinology & Metabolism*, 86(6), 2687-2696.

Pagotto, Uberto & Renato Pasquali (2006). The role of the endocannabinoid pathway in metabolism and diabetes. *Current Opinion in Endocrinology and Diabetes*, 13, 171-178.

Palermo, Francesco Alessandro, Gilberto Mosconi, Matteo Alessandro Avella, Oliana Carnevali, Maria Cristina Verdenelli, Cinzia Cecchini, & Alberta Maria Polzonetti-Magni (2011). Modulation of cortisol levels, endocannabinoid receptor 1A, proopiomelanocortin and thyroid hormone receptor alpha mRNA expressions by probiotics during sole (*Solea solea*) larval development. *General and Comparative Endocrinology*, 171(3), 293-300.

Porcella, Anna, Giorgio Marchese, Maria Antoinetta Casu, Antonio Rocchitta, Maria Letizia Lai, Gian Luigi Gessa, & Luca Pani (2002). Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. *European Journal of Endocrinology*, 147, 255-261.

Rodríguez de Fonseca, Fernando, Tibor Wenger, Miguel Navarro, & Laura L. Murphy (1999). Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. *Brain Research*, 841(1-2), 114-122.

Scopinho, América A., Francisco S. Guimarães, Fernando M. A. Corrêa, & Leonardo B. M. Ressel (2011). Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists. *Pharmacology, Biochemistry and Behavior*, 98, 268-272.

Shi, Y., M. Zou, E. Y. Baitei, A. S. Alzahrani, R. S. Parhar, Z. Al-Makhalafi, & F. A. Al-Mohanna (2008). Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. *Cancer Gene Therapy*, 15, 101-107.

Tasker, Jeffrey (2013). Endogenous cannabinoids take the edge off neuroendocrine responses to stress. *Endocrinology*, 145(12), 5429-5430.

Vemuri, V. Kiran, David R. Janero, & Alexandros Makriyannis (2008). Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. *Physiological Behavior*, 93, 671-686.

Weiss, Lola, Michael Zeiram Shoshana Reich, Shimon Slavin, Itamar Raz, Raphael Mechoulam, & Ruth Gallily (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology*, 54, 244-249.

Ziv, Ehud, Lola Weiss, Itamar Raz, Natan Patlas, Zhanna Yekhtin, & Ruth Gallily (2012).
Islet protection and amelioration of diabetes type 2 in Psammomys obesus by treatment
with cannabidiol. *Journal of Diabetes Mellitus*, 2(1), 27-34.

Chapter IX: Reproductive Health and Gynecological Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the reproductive system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the reproductive system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the reproductive system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for reproductive disorders.

The Endocannabinoid System and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, endometriosis has been associated with endocannabinoid deficiency (CECD) and the disease is categorized as genetic, originating from a hereditary source. The presentation of breast cancer as well to the assessment adds the categorization of idiopathic autoimmune to the diagnosis. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the reproductive system, which is directly affected by the immunological and neurological systems. Indeed, research supports that plant-derived cannabidiol (CBD) has analgesic and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol (CBD) may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert

antioxidant, antimicrobial, and anti-tumoral properties, rendering it valuable in the prevention and treatment of reproductive disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects which are beneficial in the prevention and management of certain reproductive disorders.

Human Reproductive System
The reproductive system is comprised of sexual organs, which define the gender of the species. Reproductive organs facilitate procreation and sexual pleasure in human beings. Stressful lifestyles, environmental factors, and genetic influences affect sexual behavior and health in males and females. For example, sexually transmitted diseases, such as HIV, affect the immune system and inhibit the ability of the individual to fight opportunistic infections. The influence of the endocannabinoid system, with excitatory CB1 receptors and immunological CB2 receptors located throughout the reproductive system, is essential in understanding disorders which affect reproductive health.

Reproductive Disorders and Diseases: Endometriosis
Endometriosis is a painful, inflammatory disease in which endometrial tissue resides in the abdominal cavity. Affected by monthly hormonal changes, endometriosis proliferates, causing intra-abdominal bleeding and adhesions. Infrequently, endometriosis can progress to other organs, including the lungs. Even with hormonal and surgical intervention, endometriosis causes chronic pain and disability for millions of women. Often accompanied by mood fluctuations, case studies support the use of low dose THC in combination with CBD to manage PMS/PMDD, which may be associated with endometriosis.

The endocannabinoid system regulates hormonal imbalance in the reproductive system. CB2 receptors are affected by clinical endocannabinoid deficiency in endometriosis and phytocannabinoid replacement increases anandamide binding to the CB2 receptors. The anti-inflammatory and analgesic properties of cannabidiol (CBD) are effective adjunctively in the management of inflammatory conditions, such as endometriosis, and may be considered in individual plans of care.

Endometrial Cancer
Endometrial adenocarcinoma causes intra-abdominal masses in women. Early detection is associated with improved prognosis, but treatment is radiation and chemotherapy. Clinical endocannabinoid deficiency (CECD) associated with endometrial adenocarcinoma is idiopathic autoimmune, with deficits affecting CB2 receptors. Cannabidiol (CBD) has been shown to reduce tumor growth and inhibit metastasis and is therefore warranted as adjunctive therapy in

malignancy. Additionally, symptom relief with cannabidiol includes analgesia and reduced anxiety associated with the diagnosis.

Prostate Cancer
Prostate cancer affects millions of men and is associated with an excellent prognosis in early detection. Because many men do not receive prostate examinations and PSH screenings, later detection is associated with poor prognosis secondary to metastasis. Clinical endocannabinoid deficiency (CECD) in prostate cancer affects primarily the CB2 receptors and is considered idiopathic autoimmune. Preventatively, in early detection, and adjunctively with radiation or surgical intervention, cannabidiol (CBD) is suggested to maintain prostate health and inhibit metastasis of malignant cells in confirmed disease.

Testicular Cancer
Testicular cancer is a life-threatening malignancy that affects men across the life-span. Because of the proximity to the lymph system, testicular cancer is difficult to manage unless detected early in the disease. Categorized as an idiopathic autoimmune clinical cannabinoid deficiency (CECD), testicular cancer responds to adjunctive use of cannabidiol. CBD has been demonstrated to reduce malignant cell metastasis and is therefore recommended adjunctively in management of this disease process.

Endocannabinoid Deficiency (CECD) Classification: Reproductive Disorders

Disorder	Origin of CECD
Endometrial Cancer	Idiopathic Autoimmune
Endometriosis	Idiopathic Autoimmune
Prostate Cancer	Idiopathic Autoimmune
Testicular Cancer	Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System Reproductive Disorder Application
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: Cannabis sativa for endometrial adenocarcinoma may be purchased at a dispensary. An example prescription follows:

Jayne Lacey
DOB: 08-29-1965
Diagnosis: Endometrial adenocarcinoma, ICD-9: 182.0
CS: 19%/1-3%
Use via vaporizer every six hours as needed.
Victor Beall, M.D.

Composition Assignments
1. Please answer the following question. Medical cannabis is a suitable adjunctive therapy for the patient with endometriosis.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the reproductive system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Agirregoitia, Ekaitz, Arkaitz Carracedo, Nerea Subirán, Asier Valdivia, Naiara Agirregoitia, Laura Peralta, Guillermo Velasco, & Jon Irazusta (2010). The CB2 cannabinoid receptor regulates human sperm cell motility. *Fertility and Sterility*, 93(5), 1378-1387.

Ambrosini, Annarina, Rosamaria Fiorini, & Giovanna Zolese (2010). Endocannnabinoids and human sperm cells. *Pharmaceuticals*, 3, 3200-3211.

Ayakannu, Thangesweran, Anthony H. Taylor, Timothy H. Marczylo, Jonathon M. Willets, & Justin C. Konje (2013). The endocannabinoid system and sex steroid hormone-dependent cancers. *International Journal of Endocrinology*, 1-14.

Ayakannu, Thangesweran, Anthony H. Taylor, Timothy H. Marczylo, Jonathon M. Willets, Laurence Brown, Quentin Davies, Esther Moss, & Justin C. Konje (2014). Association of cannabinoid receptor expression with anadamide concentrations in endometrial cancer. *The Lancet*, 383(1), S23.

Bambang, Katerina N., Tulay Karasu, Alpha Gebeh, Anthony H. Taylor, Timothy H. Marczylo, Patricia Lam, Jonathan M. Willets, & Justin C. Konje (2010). From fertilization to implantation in mammalian pregnancy-modulation of early human reproduction by the endocannabinoid system. *Pharmaceuticals*, 3(9), 2910-2929.

Bambang, Katerina N., David G. Lambert, Patricia M. W. Lam, Siobhan Quenby, Mauro Maccarrone, & Justin C. Konje (2012). Immunity and early pregnancy events: are endocannabinoids the missing link? *Journal of Reproductive Immunology*, 96, 8-18.

Battista, Natalia, Rosaria Meccariello, Gilda Cobellis, Silvia Fasano, Monia di Tommaso, Valentina Pirazzi, Justin C. Konje, Riccardo Pierantoni, & Mauro Maccarrone (2012). The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. *Molecular and Cellular Endocrinology*, 355(1), 1-14.

Battista, Natalia, Cinzia Rapino, Monia di Tommaso, Monica Bari, Nicoletta Pasquariello, & Mauro Maccarrone (2008). Regulation of male fertility by the endocannabinoid system. *Molecular and Cellular Endocrinology*, 286S, S17-S23.

Belue, Rusoun C., Allyn C. Howlett, Tracy M. Westlake, & Donald E. Hutchings (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. *Neurotoxicology and Teratology*, 17(1), 25-30.

Bovolin, Patrizia, Erika Cottone, Valentina Pomatto, Silvia Fasano, Riccardo Pierantoni, Gilda Cobellis, & Rosaria Meccariello (2014). Endocannabinoids are involved in male vertebrate reproduction: regulatory mechanisms at central and gonadal level. *Frontiers in Endocrinology*, 5(54), 1-8.

Bradshaw, Heather & Cassandra Allard (2011). Endogenous cannabinoid production in the rat female reproductive tract is regulated by changes in the hormonal milieu. *Pharmaceuticals*, 4(6), 933-949.

Brighton, Paul J., Timothy H. Marczylo, Shashi Rana, Justin C. Konje, & Jonathon M. Willets (2011). Characterization of the endocannabinoid system, CB1 receptor signaling and desensitization in human myometrium. *British Journal of Pharmacology*, 164(5), 1479-1494.

Brown, Iain, Maria G. Cascio, Klaus W. J. Wahle, Reem Smoum, Raphael Mechoulam, Ruth A. Ross, Roger G. Pertwee, & Steven D. Heys (2010). Cannabinoid-receptor dependent and –independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and –negative prostate cancer cell lines. *Carcinogenesis*, 31(9), 1584-1591.

Cacciola, Giovanna, Rosanna Chianese, Teresa Chioccarelli, Vincenza Ciaramella, Silvia Fasano, Riccardo Pierantoni, Rosario Meccariello, & Gilda Cobellis (2010). Cannabinoids and reproduction: a lasting and intriguing history. *Pharmaceuticals,* 3(10), 3275-3323.

Cacciola, Giovanna, Teresa Chioccarelli, Silvia Fasano, Riccardo Pierantoni, & Gilda Cobellis (2013). Estrogens and spermiogenesis: new insights from type 1 cannabinoid receptor knockout mice. *International Journal of Endocrinology*, 1-12.

Cacciola, Giovanna, Teresa Chioccarelli, Giulia Ricci, Rosaria Meccariello, Silvia Fasano, Riccardo Pierantoni, & Gilda Cobellis (2008). The endocannabinoid system in vertebrate male reproduction: a comparative overview. *Molecular and Cellular Endocrinology*, 286S, S24-S30.

Caffarel, María M., Clara Andradas, Eduardo Pérez-Gómez, Manuel Gumán, & Cristina Sánchez (2012). Cannabinoids: a new hope for breast cancer therapy? *Cancer Treatment Reviews*, 38, 911-918.

Dall'Aglio, C., P. Millán, M. Maranesi, P. G. Rebollar, G. Brecchia, M. Zerani, A. Gobbetti, G. Gonzalez-Mariscal, & C. Boiti (2013). Expression of the cannabinoid receptor type 1 in the pituitary of rabbits and its role in the control of LH secretion. *Domestic Animal Endocrinology*, 45(4), 171-179.

Das, S. K., B. C. Paria, I. Chakraborty, & S. K. Dey (1995). Cannabinoid ligand-receptor signaling in the mouse uterus. *Proceedings of the National of the Academy of Sciences*, 92, 4332-4336.

Dennedy, Michael C., Ann M. Friel, Diarmaid D. Houlihan, Venita M. Broderick, Terry Smith, & John J. Morrison (2004). Cannabinoids and the human uterus during pregnancy. *American Journal of Obstetrics and Gynecology*, 190(1), 2-9.

DiBlasio, Anna Maria, Michele Vignali, & David Gentilini (2013). The endocannabinoid pathway and the female reproductive organs. *Journal of Molecular Endocrinology*, 50, 81-89.

El-Talatini, Mona R., Anthony H. Taylor, Janine C. Elson, Laurence Brown, Allan C. Davidson, & Justin C. Konje (2009). Localisation and function of the endocannabinoid system in the human ovary. *PLoS One*, 4(2), 1-12.

Fasano, Silvia, Rosaria Meccariello, Gilda Cobellis, Rosanna Chianese, Giovanna Cacciola, Teresa Chioccarelli, & Riccardo Pierantoni (2009). The endocannabinoid system: an ancient signaling involved in the control of male fertility. *Annals of the New York Academy of Sciences*, 1163(1), 112-124.

Feinshtein, Valeria, Offer Erez, Zvi Ben-Zvi, Noam Erez, Tamar Eshkoli, Boaz Sheizaf, Mahmud Huleihel, & Gershon Holcberg (2013). Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. *PeerJ*, 153, 1-19.

Feinshtein, Valeria, Offer Erez, Zvi Ben-Zvi, Tamar Eshkoli, Boaz Sheizaf, Eyal Sheiner, & Gershon Holcberg (2013). Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. *American Journal of Obstetrics & Gynecology*, 573, 1-5.

Fonseca, Bruno M., Georgina Correia-da-Silva, Anthony H. Taylor, Justin C. Konje, Stephen C. Bell, & Natércia A. Texieira (2009). Spatio-temporal expression of patterns of anadamide-binding receptors in rat implantation sites: evidence for a role of the endocannabinoid system during the period of placental development. *Reproductive Biology and Endocrinology*, 7(121), 1-13.

Fonseca, B. M., N. A. Texeira, M. Almada, A. H. Taylor, J. C. Konje, G. Correia-da-Silva (2011). Modulation of the novel cannabinoid receptor-GPR55-during rat fetoplacental development. *Placenta*, 32(6), 462-469.

Fride, Esther (2004). The endocannabinoid-CB1 receptor system in pre- and postnatal life. *European Journal of Pharmacology*, 500, 289-297.

Gammon, C. Michael, G. Mark Freeman, Jr, Weihua Xie, Sandra L. Petersen, & William C. Wetsel (2005). Regualtion of gonadotropin-releasing hormone secretion by cannabinoids. *Endocrinology*, 146(10), 4491-4499.

Gorzalka, Boris B., Matthew N. Hill, & Sabrina C. H. Chang (2010). Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. *Hormones and Behavior*, 58, 91-99.

Grimaldi, Paola, Pierangela Orlando, Sara di Siena, Francesca Lolicato, Stefania Petrosino, Tiziana Bisogno, Raffaele Geremia, Luciano de Petrocellis, & Vincenzo di Marzo (2009). The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. *Proceedings of the National Academy of Sciences*, 106(27), 1-6.

Habayeb, Osama M. H., Stephen C. Bell, & Justin C. Konje (2002). Endogenous cannabinoids: metabolism and their role in reproduction. *Life Sciences*, 70(17), 1963-1977.

Horne, Andrew W., John A. Phillips, III, Nicole Kane, Paula C. Lourenco, Sarah E. McDonald, Alistair R. W. Williams, Carlos Simon, Sudhansu K. Dey, & Hiliary O. D. Critchley (2008). CB1 expression is attenuated in fallopian tube and decidua of women with ectopic pregnancy. *PLoS One*, 3(12), 1-6.

Jiang, Shuxian, Yigong Fu, John Williams, JodiAnne Wood, Lakshmipathi Pandarinathan, Shiri Avraham, Alexandros Makriyannis, Shalom Avraham, & Hava Karsenty Avraham (2007). Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. *PLoS One*, 2(7), 1-8.

Kellert, Brian A., Mike C, Nguyen, Cara Nguyen, Que H. Nguyen, & Edward J. Wagner (2009). Estrogen rapidly attenuates cannabinoid-induced changes in energy homeostasis. *European Journal of Pharmacology*, 622(1-3), 15-24.

Kessler, Cherie A., Kenneth K. Moghadam, Jennifer K. Schroeder, Arthur R. Buckley, Anoop K. Brar, & Stuart Handwerger (2005). Cannabinoid receptor 1 activation markedly inhibits human decidualization. *Molecular and Cellular Endocrinology*, 229(1-2), 201-207.

Lewis, Sheena E. & Mauro Maccarrone (2009). Endocannabinoids, sperm biology, and human fertility. *Pharmacological Research*, 60(2), 126-131.

Lewis, Sheena E. M., Cinzia Rapino, Monia di Tommaso, Mariangela Pucci, Natalia Battista, Rita Paro, Luke Simon, Deborah Lutton, & Mauro Maccarrone (2012). Differences in the endocannabinoid system of sperm from fertile and infertile men. *PLoS One*, 7(10), 1-8.

Ligresti, Alessia, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano de Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco, & Vincenzo di Marzo (2006). Antitumor activity of cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *The Journal of Pharmacology and Experimental Therapeutics*, 318, 1375-1387.

Maccarrone, M. (2008). CB2 receptors in reproduction. *British Journal of Pharmacology*, 153(2), 189-198.

Meccariello, Rosaria, Natalia Battista, Heather B. Bradshaw, & Habin Wang (2014). Endocannabinoids and reproduction. *International Journal of Endocrinology*, 1-2.

Meccariello, Rosaria, Natalia Battista, Heather B. Bradshaw, & Habin Wang (2014). Updates in reproduction coming from the endocannabinoid system. *International Journal of Endocrinology*, 1-16.

Miguel, Rosario de, Julián Romero, Raúl M. Muñoz, Lucía García-Gil, Sara González, Maria A. Villanua, Alexandros Makriyannis, José A. Ramos, & J. Javier Fernández-Ruiz (1998). Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. *Biochemical Pharmacology*, 56(10), 1331-1338.

Murase, Ryuichi, Rimi Kawamura, Eric Singer, Arash Pakdel, Pranamee Sarma, Jonathan Judkins, Eiman Elwakeel, Sonali Dayal, Esther Martinez-Martinez, Mukkanti Amere, Ramesh Gujjar, Anu Mahadevan, Pierre-Yves Desprez, & Sean D. McAllister (2014). Targeting multiple cannabinoid anti-tumor pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. *British Journal of Pharmacology*, 171, 4464-4477.

O'Connell, M. E., G. A. Morrill, G. I. Fujimoto, & A. B. Kostellow (1987). Factors affecting the response of the female rat reproductive system to cannabinoids. *Toxicology and Applied Pharmacology*, 88, 411-417.

Paria, B. C., S. K. Das, & S. K. Dey (1995). The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. *Proceedings of the National Academy of Sciences*, 92, 9460-9464.

Park, B, H. M. Gibbons, M. D. Mitchell, &M. Glass (2003). Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. *Placenta*, 24(10), 990-995.

Park, Boram, John M. McPartland, & Michelle Glass (2004). Cannabis, cannabinoids and reproduction. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 70(2), 189-197.

Peralta, L. E. Agirregoitia, R. Mendoza, A. Expósito, L. Casis, R. Matorras, & N. Agirregoitia (2011). Expression and localization of cannabinoid receptors in human immature oocytes and unfertilized metaphase-II oocytes. *Reproductive Biomedicine Online*, 23, 372-379.

Petrocellis, Luciano de, Alessia Ligresti, Aniello Schiano Moriello, Mariagrazia Iappelli, Roberta Verde, Colin G. Stott, Luigia Cristino, Pierangelo Orlando, & Vincenzo di Marzo (2012). Non-THC cannabinoids inhibit prostate carcinoma growth *in vitro* and *in vivo*: pro-apoptotic effects and underlying mechanisms. *British Journal of Pharmacology*, 168, 79-102.

Psychoyos, Delphine, K. Yaragudri Vinod, Jin Cao, Richard L. Hyson, Bogdan Wiodarczyk, Weimin He, Thomas B.Cooper, Basalingappa L. Hungund, & Richard H. Finnell (2012). Cannabinoid receptor 1 signaling in embryo neurodevelopment. *Birth Defects Research and Birth Development Reproductive Toxicology*, 95(2), 137-150.

Rapino, Cinzia, Natalia Battista, Monica Bari, & Mauro Maccarrone (2014). Endocannabinoids as biomarkers of human reproduction. *Human Reproduction Update*, 20(4), 501-516.

Resuehr, David, Dana R. Glore, Hugh S. Taylor, Kaylon L. Bruner-Tran, & Kevin G. Osteen (2012). Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). *Fertility and Sterility*, 98(4), 948-956.

Rossato, M., C. Pagano, & R. Vettor (2008). The cannabinoid system and male reproductive functions. *Journal of Neuroendocrinology*, 20(s1), 90-93.

Sreevalsan, Sandeep, Sonia Joseph, Indira Jutooru, Gayathri Chadalapaka, & Stephen H. Safe (2011). Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. *Anticancer Research*, 31(11), 3799-3807.

Stuart, Jordyn M., Jason J. Paris, Cheryl Frye, & Heather B. Bradshaw (2013). Brain levels of prostaglandins, endocannabinoids, and related lipids are affected by mating strategies. *International Journal of Endocrinology*, 1-14.

Sun, Xiaofei & Sudhansu K. Dey (2008). Aspects of endocannabinoid signaling in peri-implantation biology. *Molecular and Cellular Endocrinology*, 286(1-2), S3-11.

Sun, Xiaofei & Sudhansu K. Dey (2012). Endocannabinoid signaling in female reproduction. *American Chemical Society Chemical Neuroscience*, 3(5), 349-355.

Takeda, Shuso, Shunsuke Okajima, Hiroko Miyoshi, Kazutaka Yoshida, Yoshiko Okamoto, Tomoko Okada Toshiaki Amamoto, Kazuhito Watanabe, Curtis J. Omiecinski, Hironori Aramaki (2012). Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. *Toxicology Letters*, 214, 314-319.

Taylor, A. H., C. Ang, S. C. Bell, & J. C. Konje (2007). The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. *Human Reproduction Update*, 13(5), 501-513.

Taylor, Anthony H., Mark Finney, Patricia M. W. Lam, & Justin C. Konje (2011). Modulation of the endocannabinoid system in viable and non-viable first trimester pregnancies by pregnancy-related hormones. *Reproductive Biology and Endocrinology*, 9(152), 1-18.

Wang, Haibin, Sudhansu K. Dey, & Mauro Maccarrone (2006). Jekyll and Hyde: two faces of cannabinoid signaling in male and female fertility. *Endocrine Reviews*, 27(5), 427-448.

Wenger, Tibor, Catherine Ledent, Valer Csernus, & Ida Gerendai (2001). The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. *Biochemical and Biophysical Research Communications*, 284, 363-368.

Chapter X: Dental Health and Dental Disease

Learning Objectives
1. Discuss assessment protocols to determine level of endocannabinoid deficiencies of the dental system.
2. Discuss therapeutic strategies to address endocannabinoid deficiencies of the dental system.
3. Discuss patient care guidelines to implement cannabinoid therapy with standard of care pharmaceutical regimens pertaining to the dental system.
4. Discuss educational guidelines for patients to monitor clinical outcomes when implementing cannabinoid protocols for dental disorders.

The Endocannabinoid System and Cannabidiol (CBD) - Introduction
The endocannabinoid system (ECS) is a lipid-derived signaling system discovered within the past decade. Cannabinoids, which are homeostatic regulators, circulate throughout human and animal systems continuously, affecting all physiological processes. The endocannabinoid system is comprised of CB1 and CB2 receptors, which bind directly or indirectly to cannabinoids and phytocannabinoids, CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney. CB2 receptors regulate immunological responses and are located in the immune and circulatory systems. Endogenous compounds, such as anandamide and arachidonylglerol (2-AG), are made by mammals from lipids and bind directly to the CB1 and CB2 receptors, serving as neurotransmitters for cannabinoids. Cannabidiol (CBD oil), a non-psychotropic cannabinoid naturally occurring in human and animal species, is also a phytocannabiniod, derived from the industrial hemp plant. While CBD does not bind directly with receptors, it does affect stress genes, such as Soat2 and Cyp27a1, which control sterol (i.e., cholesterol) metabolism. CBD increases the amount of anandamide and other vital lipids, thereby indirectly increasing the availability of circulating cannabinoids to bind with CB1 and CB2 receptors.

Research has shown that cannabidiol, in the form of CBD oil, has therapeutic benefits individually and adjunctively with other interventions, Cannabidiol (CBD) made from legal, industrial hemp contains less than .3% THC, rendering it non-psychoactive. CBD oil has antiemetic, anxiolytic, antitumoral, and immunologically inhibitory properties. Three categories differentiate the types of clinical endocannabinoid deficiency (CECD), which are associated with different disease process and disorders: genetic, acquired, and idiopathic autoimmune. Many disorders have a combination of CECD origins, and supplementation with cannabidiol (CBD) requires ongoing assessment to facilitate optimal benefit for the individual.

The Human Endocannabinoid System
The human endocannabinoid system is responsible for memory networks in the brain, both excitatory and inhibitory, including the neurogenesis of hippocampal granule cells, which regulate the timing of the endocannabinoids in accordance with the brain's needs, pain perception, mood, synaptic plasticity, motor learning, appetite and taste regulation, and metabolic function, which regulates the storage of energy and transport of cellular nutrition. Cannabinoid receptor binding sites are located in the forebrain areas associated with higher cognitive function, forebrain, midbrain, and hindbrain areas associated with movement control,

and hindbrain areas associated with motor and sensory functions attributed to the autonomic nervous system. The endocannabinoid system affects the lipocytes and fat cells, collectively known as adipocytes, hepatocytes, in the gastrointestinal tract, musculoskeletal system, and endocrine system. The endogenous arachidonate-based lipids, anandamide and 2-arachidonoylglycerol (2-AG) are physiological ligands for the cannabinoid receptors. Cannabinoid receptors CB1 and CB2, two G-protein-coupled receptors, facilitate the responses of the endocannabinoid system in the body, which are critical to maintaining homeostasis. CB1 receptors are located in the central and peripheral nervous systems, as well as the lungs, kidneys, and liver. CB2 receptors are predominantly expressed in the immune system and hematopoietic cells.

The direct effect of the endocannabinoid deficiency (CECD) correlates with multisystemic clinical outcomes in such conditions as hyperinsulinemia, osteoporosis, diabetes, dementia, cardiovascular disease, multiple sclerosis, and obesity. Three primary categories are herein defined to discuss endocannabinoid deficiency (CECD): genetic, acquired, and idiopathic autoimmune. Genetic endocannabinoid deficiency (CECD) relates to hereditary acquisition of a disorder; acquired refers to an infectious of traumatic origination, and idiopathic autoimmune refers to etiologies for endocannabinoid deficiencies (CECD) which do not have direct associations. Diseases and disorders are assigned to one or more of these categories because often secondary disorders arise with physiological changes associated with the primary diagnosis. For example, periodontal disease has been associated with endocannabinoid deficiency and the disease is categorized as acquired, originating from an extrinsic source. The presentation of oral cancer, which affects the immune system, supports adding the category of idiopathic autoimmune as well to the assessment. Because the endocannabinoid system facilitates communication and coordination between various cell types, deficiencies directly affect physiological homeostasis.

Cannabidiol (CBD), a non-psychotropic cannabinoid naturally occurring in human and animal species, occurs as a phytocannabinoid, CBD oil, which is derived from the industrial hemp plant. The restorative effects of cannabidiol (CBD oil), which increases anandamide and other lipid neurotransmitters, thereby restoring the endocannabinoid system, are of interest in the medical management of multiple disorders, including disorders of the dental system, which is directly affected by the immunological system. Indeed, research supports that plant-derived cannabidiol (CBD) has analgesic and anti-inflammatory benefits.

Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychotropic and non-toxic compound, which has been demonstrated to positively affect the human endocannabinoid system. Cannabidiol (CBD), derived from the hemp plant, demonstrates anti-inflammatory and immune-modulating properties. Cannabidiol (CBD) has a low affinity for CB1 and CB2 receptors in the human body, but acts as an indirect antagonist of their agonists. (Antagonists are defined as substances that stop or inhibit the effects of another substance on the cellular surface, producing the same effect as a substance which would normally bind to the receptor. Agonists are chemicals that bind to receptors and elicit a biological response.) Therefore, cannabidiol may enhance the therapeutic effects of THC, possibly by increasing the density of the CB1 receptors. Cannabidiol (CBD) has been demonstrated to cross the blood-brain barrier and exert antioxidant,

antimicrobial, and analgesic properties, rendering it valuable in the prevention and treatment of dental disorders and diseases.

Tetrahydrocannabinol (THC) is the active ingredient in the cannabis plant. THC, a cannabinoid compound, binds to CB1 cannabinoid receptors in the human brain, simulating the naturally occurring cannabinoids produced by the human body. In the human body, CB1 receptors are located in the cerebral cortex, which describes the frontal regions of the brain, the basal ganglia, the cerebellum, the hypothalamus, the anterior congulate cortex, and the hippocampus. THC inhibits the release of neurotransmitters, including Glutamate, GABA, noradrenalin, dopamine, 5-HT, and acetylcholine. Despite the rapid inactivation of THC by the fatty acid amide hydrolase, THC, and other exogenous cannabinoids, are sustainable for extended periods of time and are associated with physiological effects which are beneficial in the prevention and management of certain dental disorders.

Human Dental System
The human dental system includes teeth, gum, and oral cavity structures. Twenty primary and twenty-eight to thirty-two permanent teeth are included in the anatomical naming of tooth structures. Endocannabinoid receptors, both CB1 and CB2, are disseminated throughout the gums, tongue, salivary glands, maxillary and mandibular structures and glands, and oral cavity. Clinical endocannabinoid deficiency (CECD) in dental disease increases the incidence of infections and systemic disorders, including dissemination to the brain and heart.

Dental Disorders and Diseases: Periodontal Disease
Periodontal disease is generally considered an acquired Clinical Endocannabinoid Deficiency (CECD), secondary to behaviors which increase the incidence of disease: poor oral hygiene, cigarette smoking, and oral tobacco use. As adjunctive treatment with oral rinses and improved dental hygiene, cannabidiol (CBD) is recommended to alleviate the discomfort associated with the disease and also reduce the inflammatory processes. Research indicates improvement with administration of cannabidiol (CBD) and reduction in painful tissues within the oral cavity.

Submandibular Gland Inflammation
Submandibular gland inflammation is an acquired clinical endocannabinoid deficiency (CECD) associated with dehydration, poor oral hygiene, and chronic inflammatory disorders.
Painful and swollen submandibular glands characterize this disorder, which responds to the analgesic and anti-inflammatory effects of cannabidiol (CBD), Consideration of adjunctive CBD oil with standard of care is warranted given research outcomes.

Endocannabinoid Deficiency (CECD) Classification: Dental Disorders

Disorder	Origin of CECD
Periodontal Disease	Acquired
Submandibular Gland Inflammation	Acquired, Idiopathic Autoimmune

CEN Medical Cannabis Pharmacological Prescription and Coding System Application
The CEN Medical Cannabis Pharmacological Prescription and Coding System (CEN/MCPPCS) provides language that enables the health care practitioner to communicate with the dispenser of medical cannabis. The first two letters of the system refer to the cannabis type: cannabis sativa, cannabis indica, or cannabis hybrida. The numerical value in percentage to the right of the colon refers to the recommended THC content in percentage, and the numerical value in sequence to the right of the THC percentage refers to the recommended CDB content.

(CEN/MCPPCS); Cannabis type (sativa, indica, hybrida; THC percentage or range/CBD percentage or range) or Hemp Cannabidiol (CBD)

Example: Cannabis sativa for periodontal disease may be purchased at a dispensary. An example prescription follows:

Larry Calder
DOB: 08-09-1966
Diagnosis: Diabetes Mellitus, ICD-9: 523.0
CS: 18%/1-3%
Use via vaporizer every six hours as needed.
Gregory Pines, D.D.S.

Composition Assignments
1. Please answer the following question. Medical cannabis is a suitable adjunctive therapy for the patient with periodontal disease.
   a. True
   b. False
2. Please go to www.libraryworld.com and enter username CEN. Select an article from the CEN library on an aspect of cannabidiol (CBD) and the dental system. Write a two hundred word critical analysis paper on this research article and determine the following in your paper:
   a. Author and affiliation
   b. Study population
   c. Purpose
   d. Outcome of the study
   e. Importance of the research

Bibliography

Beneng, K., T. Renton, Z. Yilman, Y. Yiangou, & P. Anand (2010). Cannabinoid receptor CB1-immunoreactive nerve fibers in painful and non-painful human tooth pulp. *Journal of Clinical Neuroscience*, 17, 1476-1479.

Burgos, Elisa, David Pascual, Maria Isabel Martin, & Carlos Goicoechea (2010). Anti-nociceptive effect of the cannabinoid agonist, WIN 55, 212-2, in the orofacial and temporomandibular formalin tests. *European Journal of Pain*, 14(1), 40-48.

Kalliomäki, Jarkko, Märta Segerdahl, Lynn Webster, Annika Reimfelt, Karin Huibar, Peter Annas, Rolf Karlsten, & Hans Quiding (2013). Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. *Scandinavian Journal of Pain*, 4, 17-22.

Kozono, Sayaka, Takashi Matsuyama, Kamal Krishna Biwasa, Ko-ichi Kawahara, Yumiko Nakajima, Takehiko Yoshimoto, Yutaka Yonamine, Hideshi Kadomatsu, Salunya Tancharoen, Teruto Hashiguchi, Kazuyuki Noguchi, & Ikuro Maruyama (2010). Involvement of the endocannabinoid system in periodontal healing. *Biochemical and Biophysical Research Communications*, 394, 928-933.

McDonoughy, Patrick. Joseph P. McKenna, Christine McCreary, & Eric J. Downer (2014). Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. *The International Journal of Biochemistry & Cell Biology*, 55, 72-78.

Millman, Garry, Allan J. Barnes, Ross H. Lowe, & Marilyn A. Hueets (2010). Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. *Journal of Chromatography A*, 1217(9), 1513-1521.

Mitrirattanakul, Somsak, Sopee Poomsawat, & Pornpoj Fuangtharnthip (2012). Cannabinoid receptor 1 (CB1R) expression in rat dental pulp. *Oral Science International*, 9, 17-20.

Napimoga, Marcelo H., Bruno B. Benatti, Flavia O. Lima, Polyanna M. Alves, Alline C. Campos, Diego R. Pena-dos-Santos, Fernando P. Severino, Fernando Q. Cunha, & Francisco S. Guimarães (2009). Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. *International Immunopharmacology*, 9, 216-222.

Prestifilippo, J. P., V. A. Medina, C. E. Mohn, P. A. Rodriguez, J. C. Elverdin, & J. Fernandez-Solari (2013). Endocannabinoids mediate hyposalivation induced by inflammogens in the submandibular glands and hypothalamus. *Archives of Oral Biology*, 58, 1251-1259.

Qian, Hong, Zuolin Jin, Shi Li, Na Huo, Chun Han, & Hanfei Sang (2009). Activation of CB2 cannabinoid receptors: a novel therapeutic strategy to accelerate osseointegration of dental implants. *Medical Hypotheses*, 72, 311-313.

Schwope, David M., Garry Millman, & Marilyn A. Hueets (2010). Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. *Clinical Chemistry*, 56(6), 1007-1014.